Document:

<PAGE>

                                                                    EXHIBIT 10.8

                 MASTER SEPARATION AND DISTRIBUTION AGREEMENT

                                    BETWEEN

                                SERACARE, INC.

                                      AND

                         SERACARE LIFE SCIENCES, INC.

                                 JUNE 10, 2001
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            Page
<S>                                                                         <C>
                                   ARTICLE I

                                  SEPARATION

Section 1.1    Separation Date............................................     1
Section 1.2    Closing of Transactions....................................     2
Section 1.3    Exchange of Secretary's Certificates.......................     2

                                  ARTICLE II

     DOCUMENTS AND ITEMS TO BE DELIVERED ON OR BEFORE THE SEPARATION DATE

Section 2.1    Documents To Be Delivered By SeraCare......................     2
Section 2.2    Documents to be Delivered by Life Sciences.................     3

                                  ARTICLE III

             THE DISTRIBUTION AND ACTIONS PENDING THE DISTRIBUTION

Section 3.1    Transactions Prior to the Distribution.....................     3
Section 3.2    The Distribution...........................................     4
Section 3.3    Conditions to Distribution.................................     4
Section 3.4    Sole Discretion of SeraCare................................     5

                                  ARTICLE IV

                           NONCOMPETITION AGREEMENTS

Section 4.1    Life Sciences Noncompetition Agreement.....................     6
Section 4.2    Nonsolicitation............................................     6

                                   ARTICLE V

                      MUTUAL RELEASES AND INDEMNIFICATION

Section 5.1    Life Sciences Release......................................     6
Section 5.2    SeraCare Release...........................................     6
Section 5.3    No Impairment..............................................     6
Section 5.4    No Actions As To Released Claims...........................     6
Section 5.5    Indemnification by Life Sciences...........................     7
Section 5.6    Indemnification by SeraCare................................     7
Section 5.7    Indemnified Party..........................................     7
Section 5.9    Further Instruments........................................     8
</TABLE>

                                      -i-
<PAGE>

                               TABLE OF CONTENTS
                                  (continued)

<TABLE>
<CAPTION>
                                                                                Page
<S>                                                                             <C>
                                    ARTICLE VI

                                 INSURANCE MATTERS

Section 6.1    Life Sciences Insurance Coverage After the Separation Date.....     8
Section 6.2    Cooperation and Agreement Not to Release Carriers..............     9
Section 6.3    Procedures With Respect to Insured Life Sciences Liabilities...     9
Section 6.4    Cooperation....................................................     9
Section 6.5    No Assignment or Waiver........................................     9
Section 6.6    No Liability...................................................     9
Section 6.7    Further Agreements.............................................    10

                                    ARTICLE VII

                            COVENANTS AND OTHER MATTERS

Section 7.1    Other Agreements...............................................    10
Section 7.2    Further Instruments............................................    10
Section 7.3    Agreement for Exchange of Information..........................    11
Section 7.4    Consistency with Past Practices................................    12
Section 7.5    Payment of Expenses............................................    13
Section 7.6    Dispute Resolution.............................................    13
Section 7.7    Governmental Approvals.........................................    14
Section 7.8    Cooperation in Obtaining New Agreements........................    14
Section 7.9    Confidentiality................................................    15

                                   ARTICLE VIII

                             MISCELLANEOUS PROVISIONS

Section 8.1    LIMITATION OF LIABILITY........................................    16
Section 8.2    Entire Agreement...............................................    16
Section 8.3    Governing Law..................................................    16
Section 8.4    Termination....................................................    16
Section 8.5    Notices........................................................    16
Section 8.6    Counterparts...................................................    17
Section 8.7    Binding Effect; Assignment.....................................    17
Section 8.8    Severability...................................................    17
Section 8.9    Waiver of Breach...............................................    17
Section 8.10   Amendment and Execution........................................    17
Section 8.11   Authority......................................................    17
Section 8.12   Descriptive Headings...........................................    18
Section 8.13   Gender and Number..............................................    18
Section 8.14   Additional Assurances..........................................    18
</TABLE>

                                     -ii-
<PAGE>

                               TABLE OF CONTENTS
                                  (continued)

<TABLE>
<CAPTION>
                                                                            Page
<S>                                                                         <C>
Section 8.15   Force Majeure..............................................    18
Section 8.16   Conflicting Agreements.....................................    18
Section 8.17   Survival...................................................    18
Section 8.18   Third Party Beneficiary....................................    18

                                  ARTICLE IX

                                  DEFINITIONS

Section 9.1     Action....................................................    19
Section 9.2     Adjusted Exercise Price...................................    19
Section 9.3     Ancillary Agreements......................................    19
Section 9.4     Assignment Agreement......................................    19
Section 9.5     Business Day..............................................    19
Section 9.6     Calculated Exercise Price.................................    19
Section 9.7     Commission................................................    19
Section 9.8     Confidential Information..................................    19
Section 9.9     Confidentiality Period....................................    19
Section 9.10    Disclosing Party..........................................    20
Section 9.11    Disputes..................................................    20
Section 9.12    Distribution..............................................    20
Section 9.13    Distribution Agent........................................    20
Section 9.14    Distribution Date.........................................    20
Section 9.15    Exchange Act..............................................    20
Section 9.16    Excluded Assets...........................................    20
Section 9.17    Form 10 Registration Statement............................    20
Section 9.18    Governmental Approvals....................................    20
Section 9.19    Governmental Authority....................................    20
Section 9.20    Group.....................................................    20
Section 9.21    Indemnified Party.........................................    20
Section 9.22    Indemnifying Party........................................    20
Section 9.23    Information...............................................    20
Section 9.24    Information Statement.....................................    21
Section 9.25    Insurance Policies........................................    21
Section 9.26    Insured Life Sciences Liability...........................    21
Section 9.27    Liabilities...............................................    21
Section 9.28    Life Sciences.............................................    21
Section 9.29    Life Sciences Business....................................    21
Section 9.30    Life Sciences Group.......................................    21
Section 9.31    Merger....................................................    21
Section 9.32    Merger Agreement..........................................    21
Section 9.33    Noncompetition Territory..................................    22
Section 9.34    Option Plan...............................................    22
</TABLE>

                                     -iii-
<PAGE>

                               TABLE OF CONTENTS
                                  (continued)

<TABLE>
<CAPTION>
                                                                            Page
<S>                                                                         <C>
Section 9.35    Party or Parties..........................................    22
Section 9.36    Person....................................................    22
Section 9.37    Products..................................................    22
Section 9.38    Receiving Party...........................................    22
Section 9.39    Record Date...............................................    22
Section 9.40    Separation................................................    22
Section 9.41    Separation Date...........................................    22
Section 9.42    SeraCare..................................................    22
Section 9.43    SeraCare Business.........................................    22
Section 9.44    SeraCare Group............................................    22
Section 9.45    SeraCare Options..........................................    22
Section 9.46    SeraCare Protected Business...............................    22
Section 9.47    SeraCare Warrants.........................................    23
Section 9.48    Subsidiary................................................    23
Section 9.49    Supply Agreement..........................................    23
Section 9.50    Third Party...............................................    23
Section 9.51    Transaction Agreements....................................    23
</TABLE>

                                     -iv-
<PAGE>

                 MASTER SEPARATION AND DISTRIBUTION AGREEMENT

          This Master Separation and Distribution Agreement (this "Agreement")
is entered into as of June 10, 2001, by and between SeraCare, Inc., a Delaware
corporation ("SeraCare"), and SeraCare Life Sciences, Inc., a California
corporation and wholly-owned subsidiary of SeraCare ("Life Sciences").
Capitalized terms used herein and not otherwise defined shall have the meanings
ascribed to such terms in Article IX hereof. SeraCare and Life Sciences are
sometimes referred to herein individually as a "party" or collectively as the
"parties."

                                   RECITALS

          WHEREAS, SeraCare is simultaneously herewith entering into an
Agreement and Plan of Merger (the "Merger Agreement") with Instituto Grifols,
S.A., a company organized under the laws of Spain ("Grifols"), pursuant to which
SeraCare will merge with SI Merger Corp., a Delaware corporation and wholly-
owned subsidiary of Grifols (the "Merger"), provided that all of the conditions
precedent to the Merger set forth in the Merger Agreement have been satisfied;

          WHEREAS, the Boards of Directors of SeraCare and Life Sciences have
determined that, in connection with and prior to the Merger, it is appropriate
and desirable for SeraCare to contribute and transfer to Life Sciences, and for
Life Sciences to receive and assume, substantially all of the assets and
liabilities associated with the Life Sciences Business not currently held by
Life Sciences (the "Separation");

          WHEREAS, the Board of Directors of SeraCare has determined that it is
appropriate and desirable on the terms and conditions contemplated hereby to
distribute to the holders of its common stock, $0.001 par value, by means of a
pro rata distribution immediately prior to the effective time of the Merger, all
of the shares of Life Sciences common stock (the "Distribution"), provided that
all of the conditions precedent to the Distribution set forth in this Agreement
are satisfied; and

          WHEREAS, the parties hereto desire to set forth herein the principal
transactions to be effected in connection with the Separation and the
Distribution and certain other matters relating to the relationship and the
respective rights and obligations of the parties following the Distribution.

          NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements set forth below, the parties hereto, intending to be
legally bound, agree as follows:

                                      -1-
<PAGE>

                                   ARTICLE I
                                  SEPARATION

     SECTION 1.1  Separation Date.  Unless otherwise provided in this Agreement,
                  ---------------
or in any agreement to be executed in connection with this Agreement, the
effective time and date of each transfer of property, assumption of liability,
license, undertaking, or agreement in connection with the Separation shall be
12:01 a.m., Pacific Time, immediately before the consummation of the Merger, or
such other date and time as may be fixed by the Board of Directors of SeraCare
(the "Separation Date").

     SECTION 1.2  Closing of Transactions.  Unless otherwise provided herein,
                  -----------------------
the closing of the transactions contemplated in Article II shall occur by the
lodging of each of the executed instruments of transfer, assumptions of
liability, undertakings, agreements, instruments or other documents executed or
to be executed with Proskauer Rose LLP, 1585 Broadway, New York, NY 10036
("Proskauer"), to be held in escrow for delivery as provided in Section 1.3 of
this Agreement.

     SECTION 1.3  Exchange of Secretary's Certificates.  Upon receipt of a
                  ------------------------------------
certificate of the Secretary of SeraCare in the form attached to this Agreement
as Exhibit A, SeraCare shall deliver to Life Sciences all of the items required
to be delivered by SeraCare hereunder pursuant to Section 2.1 of this Agreement
and each such item shall be deemed to be delivered to Life Sciences as of the
Separation Date upon delivery of such certificate.  Upon receipt of a
certificate of the Secretary of Life Sciences in the form attached to this
Agreement as Exhibit B, Life Sciences shall deliver to SeraCare all of the items
required to be delivered by Life Sciences pursuant to Section 2.2 hereunder and
each such item shall be deemed to be delivered to SeraCare as of the Separation
Date upon receipt of such certificate.

                                  ARTICLE II
                      DOCUMENTS AND ITEMS TO BE DELIVERED
                       ON OR BEFORE THE SEPARATION DATE

     SECTION 2.1  Documents To Be Delivered By SeraCare.  On or before the
                  -------------------------------------
Separation Date, SeraCare will deliver to Life Sciences all of the following
items and agreements (collectively, together with all agreements and documents
contemplated by such agreements, the "Ancillary Agreements"):

              (a) A duly executed General Assignment and Assumption Agreement
(the "Assignment Agreement") substantially in the form attached hereto as
Exhibit C;

              (b) A duly executed Trademark License Agreement substantially in
the form attached hereto as Exhibit D;

              (c) A duly executed Employee Matters Agreement substantially in
the form attached hereto as Exhibit E;

              (d) A duly executed Tax Matters Agreement substantially in the
form attached hereto as Exhibit F;

                                      -2-
<PAGE>

              (e) A duly executed Supply and Services Agreement substantially in
the form attached hereto as Exhibit G; and

              (f) Such other agreements, documents or instruments as the parties
may agree are necessary or desirable in order to achieve the purposes hereof.

     SECTION 2.2  Documents to be Delivered by Life Sciences.  As of the
                  ------------------------------------------
Separation Date, Life Sciences will deliver to SeraCare all of the following:

              (a) In each case where Life Sciences is a party to any agreement
or instrument referred to in Section 2.1, a duly executed counterpart of such
agreement or instrument.

                                  ARTICLE III
             THE DISTRIBUTION AND ACTIONS PENDING THE DISTRIBUTION

     SECTION 3.1  Transactions Prior to the Distribution.  Subject to the
                  --------------------------------------
conditions specified in Section 3.3, SeraCare and Life Sciences shall use their
reasonable commercial efforts to consummate the Distribution.  Such efforts
shall include, but not necessarily be limited to, those specified in this
Section 3.1.

              (a) Registration Statement.  Life Sciences, with the cooperation
                  ----------------------
and assistance of SeraCare, shall prepare a Form 10 Registration Statement (the
"Form 10 Registration Statement") in order to register the common stock of Life
Sciences under Section 12 of the Securities Exchange Act of 1934 (the "Exchange
Act"), and will, as soon as practicable following the date hereof, use its
commercially reasonably efforts to promptly file with the Securities and
Exchange Commission (the "Commission") the Form 10 Registration Statement and
such amendments or supplements thereto as may be necessary in order to cause the
Form 10 Registration Statement to become and to remain effective as required by
law, including, but not limited to, such amendments to the Form 10 Registration
Statement as may be required by the Commission or federal, state or foreign
securities laws.  SeraCare and Life Sciences shall also cooperate in preparing
and filing with the Commission any registration statements or amendments thereof
which are required to reflect the establishment of, or amendments to, any
employee benefit and other plans necessary or appropriate in connection with the
Separation, the Distribution or the other transactions contemplated by this
Agreement.

              (b) Information Statement.  SeraCare and Life Sciences shall
                  ---------------------
prepare and mail, prior to the Distribution Date, to the holders of common stock
of SeraCare, such information concerning Life Sciences and the Distribution and
such other matters as SeraCare and Life Sciences shall reasonably determine are
necessary and as may be required by law (the "Information Statement"). SeraCare
and Life Sciences will prepare, and Life Sciences will, to the extent required
under applicable law, file with the Commission any such documentation which
SeraCare and Life Sciences reasonably determine is necessary or desirable to
effectuate the Distribution, and SeraCare and Life Sciences shall each use its
reasonable commercial efforts to obtain all necessary approvals from the
Commission with respect thereto as soon as practicable.

              (c) Option Plan. SeraCare and Life Sciences shall cooperate in the
                  -----------
preparation and adoption by Life Sciences of a stock option plan (the "Option
Plan").

                                      -3-
<PAGE>

              (d) Board of Directors.  SeraCare and Life Sciences shall appoint
                  ------------------
those persons listed on Schedule 3.1(d) hereto to the Board of Directors of Life
Sciences (to the extent that such persons do not currently serve in such
capacity).

              (e) Other Actions.  SeraCare and/or Life Sciences, as appropriate,
                  -------------
shall take those actions set forth on Schedule 3.1(e) hereto.

     SECTION 3.2  The Distribution.
                  ----------------

              (a) Delivery of Shares for Distribution.  Subject to Section 3.3
                  -----------------------------------
hereof, on or prior to the date the Distribution is effective (the "Distribution
Date"), SeraCare will deliver to the distribution agent (the "Distribution
Agent") to be appointed by SeraCare to distribute to the stockholders of
SeraCare the shares of common stock of Life Sciences held by SeraCare pursuant
to the Distribution for the benefit of holders of record of common stock of
SeraCare on the Record Date, a single stock certificate, endorsed by SeraCare in
blank, representing all of the outstanding shares of common stock of Life
Sciences then owned by SeraCare, and shall cause the transfer agent for the
shares of common stock of SeraCare to instruct the Distribution Agent to
distribute on the Distribution Date the appropriate number of such shares of
common stock of Life Sciences to each such holder or designated transferee or
transferees of such holder.

              (b) Shares Received. Subject to Section 3.3, each holder of common
                  ---------------
stock of SeraCare on the Record Date (or such holder's designated transferee or
transferees) will be entitled to receive in the Distribution a number of shares
of common stock of Life Sciences equal to the number of shares of common stock
of SeraCare held by such holder on the Record Date.

              (c) Options and Warrants Received.  Subject to Section 3.3, each
                  -----------------------------
holder on the Record Date of stock options (the "SeraCare Options") or warrants
(the "SeraCare Warrants") to purchase the common stock of SeraCare will be
entitled to receive in connection with the Distribution new options or warrants,
as applicable, (i) to purchase a number of shares of Life Sciences Common Stock
equal to the number of shares underlying the SeraCare Options or SeraCare
Warrants held by such holder on the Record Date, with an exercise price equal to
the Calculated Exercise Price, and (ii) to purchase a number of shares of
SeraCare Common Stock equal to the number of shares underlying the SeraCare
Options or SeraCare Warrants held by such holder on the Record Date, with an
exercise price equal to the Adjusted Exercise Price.

              (d) Obligation to Provide Information. Life Sciences and SeraCare,
                  ---------------------------------
as the case may be, will provide to the Distribution Agent all share
certificates and any information required in order to complete the Distribution
on the basis specified above.

              (e) Conditions. SeraCare and Life Sciences shall take all
                  ----------
reasonable steps necessary and appropriate to cause the conditions set forth in
Section 3.3 to be satisfied and to effect the Distribution on the Distribution
Date.

     SECTION 3.3  Conditions to Distribution.  The obligations of the parties to
                  --------------------------
to consummate the Distribution shall be conditioned on the satisfaction, or
written waiver by SeraCare, of the following conditions:

                                      -4-
<PAGE>

              (a) Government Approvals.  Any material governmental approvals and
                  --------------------
consents necessary to consummate the Distribution shall have been obtained and
be in full force and effect.

              (b) Registration Statement. The Form 10 Registration Statement
                  ----------------------
shall have been filed and declared effective by the Commission, there shall be
no stop-order in effect with respect thereto, and the Information Statement
shall have been mailed to the holders of Common Stock of SeraCare..

              (c) No Legal Restraints. No order, injunction or decree issued by
                  -------------------
any court or agency of competent jurisdiction or other legal restraint or
prohibition preventing the consummation of the Distribution or any of the other
transactions contemplated by this Agreement shall be in effect.

              (d) Separation.  The transfer of the Life Sciences Assets and
                  ----------
assumption of the Life Sciences Liabilities shall have been effected pursuant to
Section 1.1 of the Assignment Agreement.

              (e) Option Plan.  The Option Plan shall have been duly adopted.
                  -----------

              (f) Board of Directors.  The Board of Directors of Life Sciences
                  ------------------
shall consist of the persons listed on Schedule 3.1(d).

              (g) Other Actions. The actions set forth on Schedule 3.1(e), and
                  -------------
such other actions as the parties hereto may, based upon the advice of counsel,
reasonably request to be taken prior to the Distribution in order to assure the
successful completion of the Distribution, shall have been taken.

              (h) No Material Adverse Effect. No events or developments shall
                  --------------------------
have occurred subsequent to the Separation Date that, in the judgment of the
Board of Directors of SeraCare, would result in the Distribution having a
material adverse effect on SeraCare or on the stockholders of SeraCare.

              (i) No Termination. This Agreement shall not have been terminated.
                  --------------

              (j) Merger.  All conditions precedent to the Merger (other than
                  ------
Section 9.1(e) of the Merger Agreement with respect to the Distribution) shall
have been satisfied or waived by the party for whose benefit such condition
exists and each of the parties to the Merger Agreement shall be prepared to
close the Merger immediately after the Distribution.

     SECTION 3.4  Sole Discretion of SeraCare.  SeraCare shall, in its sole and
                  ---------------------------
absolute discretion, determine the date of the consummation of the Distribution
and all terms of the Distribution, including, without limitation, the form,
structure and terms of any transaction(s) and/or offering(s) to effect the
Distribution and the timing of and conditions to the consummation of the
Distribution. In addition, SeraCare may at any time and from time to time until
the completion of the Distribution modify or change the terms of the
Distribution, including, without limitation, by accelerating or delaying the
timing of the consummation of all or part of the Distribution. Life Sciences
shall cooperate with SeraCare in all respects to

                                      -5-
<PAGE>

accomplish the Distribution and shall, at SeraCare's direction, promptly take
any and all actions necessary or desirable to effect the Distribution.
Notwithstanding this Section 3.4, SeraCare agrees that it shall not take any
actions that are inconsistent with this Agreement and the Ancillary Agreements.

                                  ARTICLE IV
                           NONCOMPETITION AGREEMENTS

     SECTION 4.1  Life Sciences Noncompetition Agreement.  Life Sciences agrees
                  --------------------------------------
that, commencing on the Distribution Date and for a period of five (5) years
thereafter, Life Sciences shall not, and shall cause its Subsidiaries not to,
engage in the SeraCare Protected Business (as herein defined) in the United
States (the "Noncompetition Territory"). The term "SeraCare Protected Business"
means owning and/or operating plasma collection facilities.

     SECTION 4.2  Nonsolicitation.    To protect SeraCare against any efforts by
                  ----------------
Life Sciences to cause employees of SeraCare to terminate their employment with
SeraCare, Life Sciences agrees that for a period of two (2) years following the
date hereof, no officer or director of Life Sciences will (i) solicit any
employee of SeraCare to accept employment with Life Sciences, or (ii) assist any
other entity in hiring any such employee, and for such two year period Life
Sciences will use reasonable efforts to prevent employees or affiliates from
making solicitations referenced in (i) or (ii) above.

                                   ARTICLE V
                      MUTUAL RELEASES AND INDEMNIFICATION

     SECTION 5.1  Life Sciences Release.  Except as provided in Section 5.3 to
                  ---------------------
this Agreement, effective as of the Separation Date, Life Sciences does hereby
release and forever discharge SeraCare and each member of the SeraCare Group
from any and all Liabilities whatsoever, whether at law or in equity (including
any right of contribution), whether arising under any contract or agreement, by
operation of law or otherwise, existing or arising from any acts or events
occurring or failing to occur or alleged to have occurred or to have failed to
occur or any conditions existing or alleged to have existed on or before the
Separation Date, including in connection with the transactions and all other
activities to implement any of the Separation and the Distribution.

     SECTION 5.2  SeraCare Release.  Except as provided in Section 5.3 to this
                  ----------------
Agreement, effective as of the Separation Date, SeraCare does hereby, for itself
and as agent for each member of the SeraCare Group, release and forever
discharge the Life Sciences and each member of the Life Sciences Group from any
and all Liabilities whatsoever, whether at law or in equity (including any right
of contribution), whether arising under any contract or agreement, by operation
of law or otherwise, existing or arising from any acts or events occurring or
failing to occur or alleged to have occurred or to have failed to occur or any
conditions existing or alleged to have existed on or before the Separation Date,
including in connection with the transactions and all other activities to
implement any of the Separation and the Distribution.

                                      -6-
<PAGE>

     SECTION 5.3  No Impairment.  Nothing contained in Section 5.1 or Section
                  -------------
5.2 shall impair any right of any Person arising under this Agreement or any
Ancillary Agreement, in each case in accordance with its terms.

     SECTION 5.4  No Actions As To Released Claims.  Life Sciences agrees, for
                  --------------------------------
itself and as agent for each member of the Life Sciences Group, not to make any
claim or demand, or commence any Action asserting any claim or demand, including
any claim of contribution or any indemnification, against SeraCare or any member
of the SeraCare Group, or any other Person released pursuant to Section 5.1,
with respect to any Liabilities released pursuant to Section 5.1. SeraCare
agrees, for itself and as agent for each member of the SeraCare Group, not to
make any claim or demand, or commence any Action asserting any claim or demand,
including any claim of contribution or any indemnification, against Life
Sciences or any member of the Life Sciences Group, or any other Person released
pursuant to Section 5.2, with respect to any Liabilities released pursuant to
Section 5.2.

     SECTION 5.5  Indemnification by Life Sciences.  Except as otherwise
                  --------------------------------
provided in this Agreement or any of the Ancillary Agreements, Life Sciences
shall indemnify, defend (including but not limited to the payment of reasonable
attorneys' fees and expenses) and hold harmless SeraCare, each member of the
SeraCare Group, Instituto Grifols, S.A. and its affiliates and each of their
respective directors, officers and employees (the "SeraCare Indemnitees") from
and against any and all Liabilities that any third party seeks to impose upon
the SeraCare Indemnitees, or which are imposed upon the SeraCare Indemnitees,
and that (without duplication) primarily relate to, arise out of or result from
(i) the Life Sciences Business prior to the Separation Date; (ii) the Life
Sciences Business after the Separation Date; (iii) any Life Sciences Liability
or any Life Sciences Contract; (iv) any breach by Life Sciences or any member of
the Life Sciences Group of the Separation Agreement or any of the Ancillary
Agreements; or (v) any Liabilities arising in connection with or resulting from
the Form 10 Registration Statement or the Information Statement. This Section
5.5 shall not apply to any amounts actually recovered from any third party
and/or covered by any insurance policy by SeraCare in respect of the related
loss, subject to the obligation to make interim payments set forth in Section
5.8 below.

     SECTION 5.6  Indemnification by SeraCare.  Except as otherwise provided in
                  ---------------------------
this Agreement or any of the Ancillary Agreements, SeraCare shall, for itself
and as agent for each member of the SeraCare Group, including Instituto Grifols,
S.A. and its affiliates, indemnify, defend (including but not limited to the
payment of reasonable attorneys' fees and expenses) and hold harmless Life
Sciences, each member of the Life Sciences Group and each of their respective
directors, officers and employees (the "Life Sciences Indemnitees") from and
against any and all Liabilities that any third party seeks to impose upon the
Life Sciences Indemnitees, or which are imposed upon the Life Sciences
Indemnitees, and that (without duplication) relate to, arise out of or result
from (i) the Life Sciences Business prior to the Separation Date to the extent
that such items are the responsibility of SeraCare pursuant to this Agreement or
the Ancillary Agreements; (ii) the SeraCare Business or any Liability of the
SeraCare Group other than the Life Sciences Liabilities; or (iii) any breach by
SeraCare or any member of the SeraCare Group of the Separation Agreement or any
of the Ancillary Agreements, including, without limitation, the obligation to
pay any Excluded Liabilities. This Section 5.6 shall not apply to any amounts
actually recovered from any third party and/or covered by any insurance policy
by Life

                                      -7-
<PAGE>

Sciences in respect of the related loss, subject to the obligation to make
interim payments set forth in Section 5.8 below.

     SECTION 5.7  Indemnified Party.  The party entitled to indemnification
                  ------------------
hereunder (the "Indemnified Party") shall promptly notify the party obligated to
provide indemnification ("the Indemnifying Party") of any claim for which
indemnification is sought pursuant to this Agreement in writing and in
reasonable detail and accompanied by reasonable supporting documentation.  With
respect to any claim made by a third party against which an Indemnified Party is
seeking indemnification hereunder, the Indemnifying Party shall have the right,
at its own expense, to participate in or assume control of the defense of such
claim, and the Indemnified Party shall fully cooperate with the Indemnifying
Party subject to reimbursement for reasonable out-of-pocket expenses incurred as
a result of such request by the Indemnifying Party.  If the Indemnifying Party
either does not elect to assume control or otherwise participate in the defense
of any third party claim, the Indemnifying Party shall be bound by the results
obtained by the Indemnified Party with respect to such claim.

     SECTION 5.8  Insurance Claims.  If SeraCare's insurance carrier fails to
                  ----------------
make a payment when due with respect to any covered claim under Section 5.5
above, then upon written notice from SeraCare, Life Sciences shall make an
interim payment to SeraCare, provided further, that if such interim payment is
made, SeraCare shall immediately assign to Life Sciences its right to recover
such claim from its insurance carrier (to the extent of the interim payment
received by SeraCare), and if payment for such claim is nonetheless made
directly to SeraCare, SeraCare shall immediately turn over the proceeds from
such claim to Life Sciences (to the extent of the interim payment received by
SeraCare). If Life Sciences's insurance carrier fails to make a payment when due
with respect to any covered claim under Section 5.6 above, then upon written
notice from Life Sciences, SeraCare shall make an interim payment to Life
Sciences, provided further, that if such interim payment is made, Life Sciences
shall immediately assign to SeraCare its right to recover such claim from its
insurance carrier (to the extent of the interim payment received by Life
Sciences), and if payment for such claim is nonetheless made directly to Life
Sciences, Life Sciences shall immediately turn over the proceeds from such claim
to SeraCare (to the extent of the interim payment received by Life Sciences).

     SECTION 5.9  Further Instruments.  At any time, SeraCare or Life Sciences
                  -------------------
will, at the request of the other, cause any member of its respective Group to
execute and deliver to the other party releases reflecting the provisions of
this Article V.

                                  ARTICLE VI
                               INSURANCE MATTERS

     SECTION 6.1  Life Sciences Insurance Coverage After the Separation Date.
                  ----------------------------------------------------------
Except as provided herein or in any Ancillary Agreement (including, without
limitation, Section 1.2(a)(v) of the Assignment Agreement), the Excluded Assets
shall include any and all rights of an insured party under each of SeraCare's
Insurance Policies.  From and after the Separation Date, Life Sciences shall be
responsible for obtaining and maintaining insurance programs for its risk of
loss and such insurance arrangements shall be separate and apart from SeraCare's
insurance programs. Notwithstanding the foregoing, SeraCare, upon the request of
Life Sciences,

                                      -8-
<PAGE>

shall use commercially reasonable efforts to assist Life Sciences in the
transition to its own separate insurance programs from and after the Separation
Date, and shall provide Life Sciences with any information that is in the
possession of SeraCare and is reasonably available and necessary either to
obtain insurance coverages for Life Sciences or to assist Life Sciences in
preventing unintended self-insurance, in whatever form.

     SECTION 6.2  Cooperation and Agreement Not to Release Carriers.  Each of
                  -------------------------------------------------
SeraCare and Life Sciences will share such information as is reasonably
necessary in order to permit the other to manage and conduct its insurance
matters in an orderly fashion. Each of SeraCare and Life Sciences, at the
request of the other, shall cooperate with and use commercially reasonable
efforts to assist the other in recoveries for claims made under any insurance
policy for the benefit of any insured party, and neither SeraCare nor Life
Sciences, nor any of their Subsidiaries, shall take any action which would
intentionally jeopardize or otherwise interfere with either party's ability to
collect any proceeds payable pursuant to any insurance policy. Except as
otherwise contemplated by this Agreement or any Ancillary Agreement, after the
Separation Date, neither SeraCare nor Life Sciences shall (and each party shall
ensure that no member of its respective Group shall), without the consent of the
other, provide any insurance carrier with a release, or amend, modify or waive
any rights under any such policy or agreement, if such release, amendment,
modification or waiver would adversely affect any rights or potential rights of
any member of the other Group thereunder. However, nothing in this Section 6.2
shall (i) preclude any member of any Group from presenting any claim or from
exhausting any policy limit, (ii) require any member of any Group to pay any
premium or other amount or to incur any Liability, or (iii) require any member
of any Group to renew, extend or continue any policy in force.

     SECTION 6.3  Procedures With Respect to Insured Life Sciences Liabilities.
                  ------------------------------------------------------------

              (a) Reimbursement. SeraCare shall seek Life Sciences' approval,
                  -------------
which approval shall not be unreasonably withheld, to incur attorneys fees,
costs (including internal costs), or any other amounts to pursue insurance
recoveries from Insurance Policies for Insured Life Sciences Liabilities.
SeraCare will bill Life Sciences and Life Sciences will reimburse SeraCare on a
monthly basis for all such amounts incurred to pursue insurance recoveries from
Insurance Policies for Insured Life Sciences Liabilities.

              (b) Management Of Claims. Except as otherwise inconsistent with
                  --------------------
the provisions of any applicable Insurance Policy, the defense of claims, suits
or actions giving rise to potential or actual Insured Life Sciences Liabilities
will be managed (in conjunction with SeraCare's insurers, as appropriate) by the
party that would have had responsibility for managing such claims, suits or
actions had such Insured Life Sciences Liabilities been Life Sciences
Liabilities.

     SECTION 6.4  Cooperation.  SeraCare and Life Sciences shall cooperate with
                  -----------
each other in all respects, and they shall execute any additional documents
which are reasonably necessary, to effectuate the provisions of this Article VI.

     SECTION 6.5  No Assignment or Waiver.  This Agreement shall not be
                  -----------------------
considered as an attempted assignment of any policy of insurance or as a
contract of insurance and shall not be

                                      -9-
<PAGE>

construed to waive any right or remedy of the SeraCare Group or the Life
Sciences Group in respect of any Insurance Policy or any other contract or
policy of insurance.

     SECTION 6.6  No Liability.  Life Sciences does hereby agree that no member
                  ------------
of the SeraCare Group shall have any Liability whatsoever as a result of the
insurance policies and practices of SeraCare and its Subsidiaries as in effect
at any time prior to the Separation Date, including as a result of the level or
scope of any such insurance, the creditworthiness of any insurance carrier, the
terms and conditions of any policy, the adequacy or timeliness of any notice to
any insurance carrier with respect to any claim or potential claim or otherwise.

     SECTION 6.7  Further Agreements.  The parties acknowledge that they intend
                  ------------------
to allocate financial obligations without violating any laws regarding
insurance, self-insurance or other financial responsibility. If it is determined
that any action undertaken pursuant to this Agreement is violative of any
insurance, self-insurance or related financial responsibility law or regulation,
the parties agree to work together to do whatever is necessary to comply with
such law or regulation while trying to accomplish, as much as possible, the
allocation of financial obligations as intended in this Agreement.

                                  ARTICLE VII
                          COVENANTS AND OTHER MATTERS

     SECTION 7.1  Other Agreements.  In addition to the specific agreements,
                  ----------------
documents and instruments that are Exhibits to this Agreement, SeraCare and Life
Sciences agree to execute or cause to be executed by the appropriate parties and
deliver, as appropriate, such other agreements, instruments and other documents
as may be necessary or desirable in order to effect the purposes of this
Agreement and the Ancillary Agreements.

     SECTION 7.2  Further Instruments.
                  -------------------

              (a) At the request of Life Sciences and without further
consideration, SeraCare will execute and deliver, and will cause its applicable
Subsidiaries to execute and deliver, to Life Sciences such other instruments of
transfer, conveyance, assignment, substitution and confirmation and, subject to
the terms and conditions hereof and in the Assignment Agreement, take such
action as Life Sciences may reasonably deem necessary or desirable in order more
effectively to transfer, convey and assign to Life Sciences and confirm Life
Sciences' title to all of the assets, rights and other things of value
contemplated to be transferred to Life Sciences pursuant to this Agreement, the
Ancillary Agreements, and any documents referred to therein, to put Life
Sciences in actual possession and operating control thereof and to permit Life
Sciences to exercise all rights with respect thereto (including, without
limitation, rights under contracts and other arrangements as to which the
consent of any third party to the transfer thereof shall not have previously
been obtained). At the request of SeraCare and without further consideration,
Life Sciences will execute and deliver, and will cause its applicable
Subsidiaries to execute and deliver, to SeraCare and its Subsidiaries all
instruments, assumptions, novations, undertakings, substitutions or other
documents and take such other action as SeraCare may reasonably deem necessary
or desirable in order to have Life Sciences fully and unconditionally assume and
discharge the liabilities contemplated to be assumed by Life Sciences under this

                                     -10-
<PAGE>

Agreement or any document in connection herewith and to relieve the SeraCare
Group of any liability or obligation with respect thereto and evidence the same
to third parties.

              (b) At the request of SeraCare and without further consideration,
Life Sciences will execute and deliver to SeraCare such other instruments of
transfer, conveyance, assignment, substitution and confirmation and, subject to
the terms and conditions hereof and in the Assignment Agreement, take such
action as SeraCare may reasonably deem necessary or desirable in order more
effectively to transfer, convey and assign to SeraCare and confirm SeraCare's
title to all of the assets, rights and other things of value contemplated to be
transferred to SeraCare pursuant to this Agreement, the Ancillary Agreements,
and any documents referred to therein, to put SeraCare in actual possession and
operating control thereof and to permit SeraCare to exercise all rights with
respect thereto (including, without limitation, rights under contracts and other
arrangements as to which the consent of any third party to the transfer thereof
shall not have previously been obtained). At the request of Life Sciences and
without further consideration, SeraCare will execute and deliver, and will cause
its applicable Subsidiaries to execute and deliver, to Life Sciences all
instruments, assumptions, novations, undertakings, substitutions or other
documents and take such other action as Life Sciences may reasonably deem
necessary or desirable in order to have SeraCare fully and unconditionally
assume and discharge the liabilities contemplated to be assumed by SeraCare
under this Agreement or any document in connection herewith and to relieve Life
Sciences of any liability or obligation with respect thereto and evidence the
same to third parties.

              (c) Neither SeraCare nor Life Sciences shall be obligated, in
connection with the foregoing, to expend money other than reasonable out-of-
pocket expenses, attorneys' fees and recording or similar fees. Each party, at
the request of the other party hereto, shall execute and deliver such other
instruments and do and perform such other acts and things as may be necessary or
desirable for effecting completely the consummation of the transactions
contemplated hereby.

     SECTION 7.3  Agreement for Exchange of Information.  Each of SeraCare and
                  -------------------------------------
Life Sciences agrees to provide, or cause to be provided, to each other, at any
time before or after the Distribution Date, as soon as reasonably practicable
after written request therefor, any Information in the possession or under the
control of such party that the requesting party reasonably requests (i) to
comply with reporting, disclosure, filing or other requirements imposed on the
requesting party (including under applicable securities laws) by a Governmental
Authority having jurisdiction over the requesting party, (ii) for use in any
other judicial, regulatory, administrative or other proceeding or in order to
satisfy audit, accounting, claims, regulatory, litigation or other similar
requirements, (iii) to comply with its obligations under this Agreement or any
Ancillary Agreement or (iv) in connection with the ongoing businesses of
SeraCare or Life Sciences, as the case may be; provided, however, that in the
event that any party determines that any such provision of Information could be
commercially detrimental, violate any law or agreement, or waive any attorney-
client privilege, the parties shall take all reasonable measures to permit the
compliance with such obligations in a manner that avoids any such harm or
consequence.  Each of SeraCare and Life Sciences shall be responsible for any
and all of their own costs incurred in connection with the forgoing.

                                     -11-
<PAGE>

          (a) Internal Accounting Controls; Financial Information.  After the
              ---------------------------------------------------
Separation Date, (i) each party shall maintain in effect at its own cost and
expense adequate systems and controls for its business to the extent necessary
to enable the other party to satisfy its reporting, accounting, audit and other
obligations, and (ii) each party shall provide, or cause to be provided, to the
other party and its Subsidiaries in such form as such requesting party shall
request, at no charge to the requesting party, all financial and other data and
information as the requesting party reasonably determines necessary or advisable
in order to prepare its financial statements, any registration statement of the
requesting party, or its parent or their affiliates, and reports or filings with
any Governmental Authority.

          (b) Ownership of Information.  Any Information owned by a party that
              ------------------------
is provided to a requesting party pursuant to this Section 7.3 shall be deemed
to remain the property of the providing party.  Unless specifically set forth
herein, nothing contained in this Agreement shall be construed as granting or
conferring rights of license or otherwise in any such Information.

          (c) Record Retention.  To facilitate the possible exchange of
              ----------------
Information pursuant to this Section 7.3 and other provisions of this Agreement
after the Distribution Date, each party agrees to use its reasonable commercial
efforts to retain all tax, employee and financial Information in its respective
possession or control on the Distribution Date.  No party will destroy, or
permit any of its Subsidiaries to destroy, any Information that exists on the
Separation Date (other than Information that is permitted to be destroyed under
the current record retention policy of such party) without first using its
reasonable commercial efforts to notify the other party of the proposed
destruction and giving the other party the opportunity to take possession of
such Information prior to such destruction.

          (d) Limitation of Liability.  No party shall have any liability to any
              -----------------------
other party in the event that any Information exchanged or provided pursuant to
this Section 7.3 is found to be inaccurate, in the absence of willful misconduct
by the party providing such Information.  No party shall have any liability to
any other party if any Information is destroyed or lost after reasonable
commercial efforts by such party to comply with the provisions of Section
7.3(c).

          (e) Other Agreements Providing for Exchange of Information.  The
              ------------------------------------------------------
rights and obligations granted under this Section 7.3 are subject to any
specific limitations, qualifications or additional provisions on the sharing,
exchange or confidential treatment of Information set forth in this Agreement
and any Ancillary Agreement.

          (f) Production of Witnesses; Records; Cooperation.  After the
              ---------------------------------------------
Distribution Date, except in the case of a legal or other proceeding by one
party against the other party (which shall be governed by such discovery rules
as may be applicable), each party hereto shall use its reasonable commercial
efforts to make available to each other party, upon written request, the former,
current and future directors, officers, employees, other personnel and agents of
such party as witnesses and any books, records or other documents within its
control or which it otherwise has the ability to make available, to the extent
that any such person (giving consideration to business demands of such
directors, officers, employees, other personnel and agents) or books, records or
other documents may reasonably be required in connection with any legal,
administrative or other proceeding in which the requesting party may from time
to time be

                                     -12-
<PAGE>

involved, regardless of whether such legal, administrative or other proceeding
is a matter with respect to which indemnification may be sought hereunder. The
requesting party shall bear all costs and expenses in connection therewith.

     SECTION 7.4  Consistency with Past Practices.  At all times prior to the
                  -------------------------------
Separation Date, SeraCare will cause Life Sciences to conduct the Life Sciences
Business in the ordinary course, consistent with past practices, including,
without limitation, the financial accounting for intercompany inventory
transfers and receivables, except as otherwise expressly provided in this
Agreement or the Ancillary Agreements.  The parties acknowledge that the amount
of such intercompany inventory transfers varies from month to month.  The
parties agree that (i) the prices for Products that will be paid by Life
Sciences from the date hereof through the Separation Date substantially conform
to the prices that would be charged and paid by the parties on the basis that
such prices have been determined through an arms' length negotiation and (ii)
except as provided herein, all management, general and administrative costs and
expenses (including without limitation the costs of insurance and legal fees and
expenses) incurred by the parties will be charged and allocated on a basis
consistent with past practices.  The parties acknowledge and agree that (i) the
cash flow transferred from Life Sciences to SeraCare from January  1, 2001 until
the date hereof will be retained by SeraCare and (ii) Life Sciences shall be
entitled to retain any cash flow generated by Life Sciences from the date hereof
through the Separation Date.

     SECTION 7.5  Payment of Expenses.  Except as otherwise provided in this
                  -------------------
Agreement, the Ancillary Agreements or any other agreement between the parties
relating to the Separation or the Distribution, all costs and expenses incurred
by the parties hereto in connection with the Separation and Distribution
(excluding internal costs and expenses of Life Sciences) shall be paid by
SeraCare.

     SECTION 7.6  Dispute Resolution.  Resolution of any and all disputes,
                  ------------------
claims and causes of action of any nature whatsoever (collectively, "Disputes"),
arising from or relating to this Agreement, shall be exclusively governed by the
provisions of this Section 7.6.

              (a) Negotiation.  The parties shall make a good faith attempt to
                  -----------
resolve any Dispute arising out of or relating to this Agreement (other than a
Dispute relating to a breach of any obligation of confidentiality, or
infringement, misappropriation, or misuse of any intellectual property right,
which may be submitted to arbitration immediately pursuant to the terms of
Section 7.6(b)) through informal negotiation between appropriate representatives
from each of SeraCare and Life Sciences.  If at any time either party feels that
such negotiations are not leading to a resolution of the Dispute, such party may
send a notice to the other party describing the Dispute and requesting a meeting
of the senior executives from each party.  Within ten (10) Business Days after
such notice is given, each party shall select appropriate senior executives of
each party who shall have the authority to resolve the matter and shall meet to
attempt in good faith to negotiate a resolution of the Dispute.  During the
course of negotiations under this Section 7.6(a), all reasonable requests made
by one party to the other for information, including requests for copies of
relevant documents, will be honored.  The specific format for such negotiations
will be left to the discretion of the designated negotiating senior executives
but may include the preparation of agreed upon statements of fact or written
statements of position furnished to the other party.  In the event that any
Dispute arising out of or related to this Agreement is not settled by the
parties within thirty (30) days after the first meeting of the

                                     -13-
<PAGE>

negotiating senior executives, either party may submit the Dispute to
arbitration pursuant to Section 7.6(b).

          (b) Arbitration.  All Disputes not resolved by good faith negotiations
              -----------
among the parties pursuant to Section 7.6(a) within the prescribed time period
shall be submitted to, and determined by, arbitration.  Such arbitration shall
proceed in accordance with the then-current rules for arbitration established by
the American Arbitration Association ("AAA"), unless the parties hereto mutually
agree otherwise, and pursuant to the following procedures:

              (i)   The parties shall attempt in good faith to select from the
     AAA panel one (1) arbitrator mutually acceptable to both parties sitting in
     the state of New York. If the parties fail to agree upon an arbitrator
     within fifteen (15) calendar days, an arbitrator shall be selected by AAA
     in pursuant to the procedures set forth in AAA Rules. The parties agree
     that for disputes involving $1 million or more exclusive of claimed
     interest, arbitration fees and costs, the procedures for "large complex
     commercial disputes" of the AAA shall apply. In the event of a conflict,
     the provisions of this Agreement will control.

              (ii)  Reasonable discovery shall be allowed in arbitration.

              (iii) All proceedings before the arbitrator shall be held in New
     York, New York.  The governing law shall be that of California.

              (iv)  The award rendered by the arbitrator shall be final and
     binding, and judgment may be entered in accordance with applicable law and
     in any court having jurisdiction thereof.

              (v)   The award rendered by the arbitrator shall include (A) a
     provision that the prevailing party in such arbitration recover its costs
     relating to the arbitration and reasonable attorneys' fees from the other
     party, (B) the amount of such costs and fees, and (C) an order that the
     losing party pay the fees and expenses of the arbitrator.

              (vi)  The arbitrator shall by the agreement of the parties
     expressly be prohibited from awarding punitive damages in connection with
     any claim being resolved by arbitration hereunder.

              (vii) All aspects of the arbitration shall be treated as
     confidential. Neither the parties nor the arbitrator may disclose to any
     third party the existence, content or results of the arbitration, except as
     necessary to enforce the award in court or to comply with legal or
     regulatory requirements.

          (c) Continuity of Service and Performance.  Unless otherwise agreed in
              -------------------------------------
writing, the parties will continue to provide service and honor all other
commitments under this Agreement and each Ancillary Agreement during the course
of dispute resolution pursuant to the provisions of this Section 7.6 with
respect to all matters not subject to such dispute, controversy or claim.

                                     -14-
<PAGE>

     Section 7.7    Governmental Approvals.  To the extent that the Separation
                    ----------------------
requires any Governmental Approvals, the parties will use their reasonable
commercial efforts to obtain any such Governmental Approvals.

     Section 7.8    Cooperation in Obtaining New Agreements.  SeraCare
                    ---------------------------------------
understands that, prior to the Separation Date, Life Sciences has derived
benefits under certain agreements between SeraCare and third parties, which
agreements are not being assigned to Life Sciences in connection with the
Separation.  Upon the request of Life Sciences, SeraCare agrees to make
introductions to appropriate Life Sciences personnel to SeraCare's contacts at
such third parties, and agrees to provide reasonable assistance to Life Sciences
so that Life Sciences may obtain agreements from such third parties under
substantially equivalent terms and conditions, including financial terms and
conditions, that apply to SeraCare.  Such assistance may include, but is not
limited to, (i) requesting and encouraging such third parties to enter into such
agreements with Life Sciences, (ii) attending meetings and negotiating sessions
with Life Sciences and such third parties, and (iii) participating in buying
consortiums with Life Sciences.  SeraCare also understands that there are
certain agreements between SeraCare and third parties, which agreements are
being assigned to Life Sciences in connection with the Separation but which may
require the consent of the applicable third party.  Upon the request of Life
Sciences, SeraCare agrees to use commercially reasonable efforts to assist Life
Sciences in seeking and obtaining the consent of such third parties to such
assignment.  The parties expect that the activities contemplated by this Section
7.8 will be substantially completed by the Distribution Date, but in no event
will SeraCare have any obligations hereunder after the first anniversary of the
Distribution Date. The parties agree that any and all costs incurred in
connection with the forgoing shall be allocated on an equitable basis to and
paid by the party expected to benefit from such costs and expenses.

     Section 7.9    Confidentiality.
                    ----------------

          (a)  Confidentiality And Non-Use Obligations.  During the
               ---------------------------------------
Confidentiality Period, the Receiving Party shall (i) protect the Confidential
Information of the Disclosing Party by using the same degree of care, but no
less than a reasonable degree of care, to prevent the unauthorized use,
dissemination, or publication of the Confidential Information as the Receiving
Party uses to protect its own Confidential Information of a like nature, (ii)
not use such Confidential Information in violation of any use restriction in any
Transaction Agreement, and (iii) not disclose such Confidential Information to
any Third Party, except as expressly permitted under this Agreement, in the
Transaction Agreements or in any other agreements entered into between the
parties in writing, without prior written consent of the Disclosing Party.

          (b)  Compelled Disclosure.  If the Receiving Party or any of its
               --------------------
respective Subsidiaries believes that it will be compelled by a court or other
authority to disclose Confidential Information of the Disclosing Party, it shall
(i) give the Disclosing Party prompt and timely written notice so that the
Disclosing Party may take steps to oppose such disclosure, but in any event the
Receiving Party shall not be prohibited from complying with such requirement and
(ii) cooperate with the Disclosing Party in its attempts to oppose such
disclosure, provided that such opposition is reasonable in light of applicable
law or regulation. If the Receiving Party complies with the above, it shall not
be prohibited from complying with such requirements to disclose, but shall
cooperate with the Disclosing Party to take all reasonable

                                     -15-
<PAGE>

steps to make such disclosure subject to a suitable protective order or
otherwise prevent unrestricted or public disclosure.

          (c)  No Restriction on Disclosing Party.  Nothing in this Agreement
               ----------------------------------
shall restrict the Disclosing Party from using, disclosing, or disseminating its
own Confidential Information in any way provided that, in so doing, it does not
use, disclose or disseminate any Confidential Information of the Receiving
Party.

          (d)  Third Party Restrictions. Nothing in the Agreement supersedes any
               ------------------------
restriction imposed by Third Parties on their Confidential Information, and
there is no obligation on the Disclosing Party to conform Third Party agreements
to the terms of this Agreement.

          (e)  Warranty Disclaimer.  EACH PARTY ACKNOWLEDGES AND AGREES THAT ALL
               -------------------
CONFIDENTIAL INFORMATION IS PROVIDED ON AN "AS IS, WHERE IS" BASIS AND THAT
NEITHER PARTY NOR ANY OF ITS SUBSIDIARIES HAS MADE OR WILL MAKE ANY WARRANTY
WHATSOEVER WITH RESPECT TO CONFIDENTIAL INFORMATION, EXPRESS, IMPLIED OR
STATUTORY, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, ENFORCEABILITY OR NON-
INFRINGEMENT.

                                 ARTICLE VIII
                           MISCELLANEOUS PROVISIONS

     Section 8.1    LIMITATION OF LIABILITY.  IN NO EVENT SHALL EITHER PARTY OR
                    -----------------------
ITS SUBSIDIARIES BE LIABLE TO THE OTHER PARTY OR ITS SUBSIDIARIES FOR ANY
SPECIAL, CONSEQUENTIAL, INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR LOST
PROFITS, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE)
ARISING IN ANY WAY OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH OTHER PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

     Section 8.2    Entire Agreement.  This Agreement, the Ancillary Agreements
                    ----------------
and the Exhibits and Schedules referenced or attached hereto and thereto,
constitute the entire agreement between the parties with respect to the subject
matter hereof and shall supersede all prior written and oral and all
contemporaneous oral agreements and understandings with respect to the subject
matter hereof.

     Section 8.3    Governing Law.  This Agreement shall be construed in
                    -------------
accordance with and all Disputes hereunder shall be governed by the laws of the
State of California, excluding its conflict of law rules.

     Section 8.4    Termination.  This Agreement and all Ancillary Agreements
                    -----------
may be terminated and the Distribution abandoned at any time prior to the
Distribution Date by and in the sole discretion of SeraCare without the approval
of Life Sciences.  This Agreement and all Ancillary Agreements shall
automatically terminate upon the termination of the Merger Agreement in
accordance with its terms.  In the event of termination pursuant to this Section
8.4, no party shall have any liability of any kind to the other party.

                                     -16-
<PAGE>

     Section 8.5    Notices.  Any notice, demand, offer, request or other
                    -------
communication required or permitted to be given by either party pursuant to the
terms of this Agreement shall be in writing and shall be deemed effectively
given the earlier of (i) when received, (ii) when delivered personally, (iii)
one (1) Business Day after being delivered by facsimile (with receipt of
appropriate confirmation), (iv) one (1) Business Day after being deposited with
an overnight courier service or (v) four (4) days after being deposited in the
U.S. mail, First Class with postage prepaid, and addressed to the attention of
the party's Chief Executive Officer at the address of its principal executive
office or such other address as a party may request by notifying the other party
thereof in writing.

     Section 8.6    Counterparts.  This Agreement, including the Schedules and
                    ------------
Exhibits hereto and the other documents referred to herein, may be executed via
facsimile or otherwise in counterparts, each of which shall be deemed to be an
original but all of which shall constitute one and the same agreement.

     Section 8.7    Binding Effect; Assignment.  This Agreement shall inure to
                    --------------------------
the benefit of and be binding upon the parties hereto and their respective legal
representatives and successors, and nothing in this Agreement, express or
implied, is intended to confer upon any other Person any rights or remedies of
any nature whatsoever under or by reason of this Agreement.  Except as herein
specifically provided to the contrary, neither party may assign this Agreement
or any rights or obligations hereunder, without the prior written consent of the
other party, and any such assignment shall be void; provided, however, that
either party (or its permitted successive assignees or transferees hereunder)
may assign or transfer this Agreement as a whole without consent to an entity
that succeeds to all or substantially all of the business or assets of such
party to which this Agreement relates.

     Section 8.8    Severability.  The parties hereto have negotiated and
                    ------------
prepared the terms of this Agreement in good faith with the intent that each and
every one of the terms, covenants and conditions herein be binding upon and
inure to the benefit of the respective parties.  Accordingly, if any one or more
of the terms, provisions, promises, covenants or conditions of this Agreement or
the application thereof to any person or circumstance shall be adjudged to any
extent invalid, unenforceable, void or voidable for any reason whatsoever by a
court of competent jurisdiction, such provision shall be as narrowly construed
as possible, and each and all of the remaining terms, provisions, promises,
covenants and conditions of this Agreement or their application to other persons
or circumstances shall not be affected thereby and shall be valid and
enforceable to the fullest extent permitted by law.  To the extent this
Agreement is in violation of applicable law, then the parties agree to negotiate
in good faith to amend this Agreement, to the extent possible consistent with
its purposes, to conform to law.

     Section 8.9    Waiver of Breach.  The waiver by either party hereto of a
                    ----------------
breach or violation of any provision of this Agreement shall not operate as, or
be construed to constitute, a waiver of any subsequent breach of the same or
another provision hereof.

     Section 8.10   Amendment and Execution.  This Agreement and amendments
                    -----------------------
hereto shall be in writing and executed in multiple copies via facsimile or
otherwise on behalf of SeraCare and Life Sciences by their respective duly
authorized officers and representatives.  Each multiple copy shall be deemed an
original, but all multiple copies together shall constitute

                                     -17-
<PAGE>

one and the same instrument. The parties hereto agree that this Agreement shall
not be amended or modified without the express written consent of Instituto
Grifols, S.A., which consent shall not be unreasonably withheld or delayed.

     Section 8.11   Authority.  Each of the parties hereto represents to the
                    ---------
other that (a) it has the corporate or other requisite power and authority to
execute, deliver and perform this Agreement, (b) the execution, delivery and
performance of this Agreement by it have been duly authorized by all necessary
corporate or other actions, (c) it has duly and validly executed and delivered
this Agreement, and (d) this Agreement is a legal, valid and binding obligation,
enforceable against it in accordance with its terms subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting creditors' rights generally and general equity principles.

     Section 8.12   Descriptive Headings.  The headings contained in this
                    --------------------
Agreement, in any Exhibit or Schedule hereto and in the table of contents to
this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.  Any capitalized term used in
any Schedule or Exhibit but not otherwise defined therein, shall have the
meaning assigned to such term in this Agreement.  When a reference is made in
this Agreement to an Article or a Section, Exhibit or Schedule, such reference
shall be to an Article or Section of, or an Exhibit or Schedule to, this
Agreement unless otherwise indicated.

     Section 8.13   Gender and Number.  Whenever the context of this Agreement
                    -----------------
requires, the gender of all words herein shall include the masculine, feminine
and neuter, and the number of all words herein shall include the singular and
plural.

     Section 8.14   Additional Assurances.  Except as may be specifically
                    ---------------------
provided herein to the contrary, the provisions of this Agreement shall be self-
operative and shall not require further agreement by the parties; provided,
however, at the request of either party, the other party shall execute such
additional instruments and take such additional acts as are reasonable, and as
the requesting party may reasonably deem necessary, to effectuate this
Agreement.

     Section 8.15   Force Majeure.  Neither party shall be liable or deemed to
                    -------------
be in default for any delay or failure in performance under this Agreement or
other interruption of service deemed to result, directly or indirectly, from
acts of God, civil or military authority, acts of public enemy, war, accidents,
explosions, earthquakes, floods, failure of transportation, strikes or other
work interruptions by either party's employees, or any other similar cause
beyond the reasonable control of either party unless such delay or failure in
performance is expressly addressed elsewhere in this Agreement.

     Section 8.16   Conflicting Agreements.  In the event of conflict between
                    ----------------------
this Agreement and any Ancillary Agreement or other agreement executed in
connection herewith, the provisions of such other agreement shall prevail.

     Section 8.17   Survival.  Except as set forth in the following sentence,
                    --------
the covenants and other agreements set forth in this Agreement shall survive the
Distribution for a period of one year and shall terminate on the anniversary of
the Distribution.  The covenants set forth in

                                     -18-
<PAGE>

Article IV, Section 7.6 and Article VIII shall survive the Distribution and
continue in effect for a period of five years.

     Section 8.18   Third Party Beneficiary.  The parties agree that Instituto
                    -----------------------
Grifols, SA shall be an express third party beneficiary to this Agreement.

                                  ARTICLE IX
                                  DEFINITIONS

     Section 9.1    Action.  "Action" means any demand, action, suit,
                    ------
countersuit, arbitration, inquiry, proceeding or investigation by or before any
federal, state, local, foreign or international governmental authority or any
arbitration or mediation tribunal.

     Section 9.2    Adjusted Exercise Price  "Adjusted Exercise Price" has the
                    -----------------------
meaning set forth in Section 3.4(c) of the Merger Agreement.

     Section 9.3    Ancillary Agreements.  "Ancillary Agreements" has the
                    --------------------
meaning set forth in Section 2.1 hereof.

     Section 9.4    Assignment Agreement.  "Assignment Agreement" has the
                    --------------------
meaning set forth in Section 2.1(a) hereof.

     Section 9.5    Business Day.  "Business Day" means a day other than a
                    ------------
Saturday, a Sunday or a day on which banking institutions located in the State
of California are authorized or obligated by law or executive order to close.

     Section 9.6    Calculated Exercise Price  "Calculated Exercise Price" has
                    -------------------------
the meaning set forth in Section 3.4(b) of the Merger Agreement.

     Section 9.7    Commission.  "Commission" has the meaning set forth in
                    ----------
Section 3.1(a) hereof.

     Section 9.8    Confidential Information.  "Confidential Information" means
                    ------------------------
any and all financial, technical, commercial or other information of SeraCare or
Life Sciences, as appropriate (whether written or oral), including, without
limitation, all information, notes, customer product specifications, client or
customer information, lists and records, reports, analyses, financial
statements, compilations, studies, forms, business or management methods,
marketing data, fee schedules, information technology systems and programs,
projections, forecasts or trade secrets of SeraCare or Life Sciences, as
applicable, whether or not such Confidential Information is disclosed or
otherwise made available to one party by the other party pursuant to this
Agreement. Confidential Information shall also include the terms and provisions
of this Agreement and any transactions consummated or documents executed by the
parties pursuant to this Agreement. Confidential Information does not include
any information that (i) is or becomes generally available to and known by the
public (other than as a result of an unpermitted disclosure directly or
indirectly by the Receiving Party or its affiliates, advisors or
representatives); (ii) is or becomes available to the Receiving Party on a
nonconfidential basis from a source other than the Disclosing Party or its
affiliates, advisors or representatives, provided that such source is not and
was not bound by a confidentiality agreement with or other

                                     -19-
<PAGE>

obligation of secrecy to the Disclosing Party; or (iii) has already been
developed, or is hereafter independently acquired or developed, by the Receiving
Party without violating any confidentiality agreement with or other obligation
of secrecy to the Disclosing Party.

     Section 9.9    Confidentiality Period.  "Confidentiality Period" means five
                    ----------------------
(5) years after either (i) the Separation Date with respect to Confidential
Information of the Disclosing Party that is known to or in the possession of the
Receiving Party as of the Separation Date or (ii) the date of disclosure with
respect to Confidential Information that is disclosed by the Disclosing Party to
the Receiving Party after the Separation Date.

     Section 9.10   Disclosing Party.  "Disclosing Party" means the party
                    ----------------
owning or disclosing the relevant Confidential Information.

     Section 9.11   Disputes.  "Disputes" has the meaning set forth in Section
                    --------
7.6 hereof.

     Section 9.12   Distribution.  "Distribution" has the meaning set forth in
                    ------------
the Recitals hereof.

     Section 9.13   Distribution Agent.  "Distribution Agent" has the meaning
                    ------------------
set forth in Section 3.2(a) hereof.

     Section 9.14   Distribution Date.  "Distribution Date" has the meaning set
                    -----------------
forth in Section 3.2(a) hereof.

     Section 9.15   Exchange Act.  "Exchange Act" has the meaning set forth in
                    ------------
Section 3.1(a) hereof.

     Section 9.16   Excluded Assets  "Excluded Assets" has the meaning set forth
                    ---------------
in Section 1.2(b) of the Assignment Agreement.

     Section 9.17   Form 10 Registration Statement.  "Form 10 Registration
                    ------------------------------
Statement" shall mean the Form 10 Registration Statement described in Section
3.1(a) hereof including any amendments or supplements thereto.

     Section 9.18   Governmental Approvals.  "Governmental Approvals" means any
                    ----------------------
notices, reports or other filings to be made, or any consents, registrations,
approvals, permits or authorizations to be obtained from, any Governmental
Authority.

     Section 9.19   Governmental Authority.  "Governmental Authority" shall mean
                    ----------------------
any federal, state, local, foreign or international court, government,
department, commission, board, bureau, agency, official or other regulatory,
administrative or governmental authority.

     Section 9.20   Group.  "Group" means either of the SeraCare Group or the
                    -----
Life Sciences Group.

     Section 9.21   Indemnified Party   "Indemnified Party" has the meaning set
                    ------------------
forth in Section 5.7 hereof.

                                     -20-
<PAGE>

     Section 9.22   Indemnifying Party. "Indemnifying Party" has the meaning set
                    ------------------
forth in Section 5.7 hereof.

     Section 9.23   Information.  "Information" means information, whether or
                    -----------
not patentable or copyrightable, in written, oral, electronic or other tangible
or intangible forms, stored in any medium, including studies, reports, records,
books, contracts, instruments, surveys, discoveries, ideas, concepts, know-how,
techniques, designs, specifications, drawings, blueprints, diagrams, models,
prototypes, samples, flow charts, data, computer data, disks, diskettes, tapes,
computer programs or other software, marketing plans, customer names,
communications by or to attorneys (including attorney-client privileged
communications), memos and other materials prepared by attorneys or under their
direction (including attorney work product), and other technical, financial,
employee or business information or data.

     Section 9.24   Information Statement  "Information Statement" has the
                    ---------------------
meaning set forth in Section 3.1(b) hereof.

     Section 9.25   Insurance Policies.  "Insurance Policies" means insurance
                    ------------------
policies pursuant to which a Person makes a true risk transfer to an insurer.

     Section 9.26   Insured Life Sciences Liability.  "Insured Life Sciences
                    -------------------------------
Liability" means any Life Sciences Liability to the extent that it is covered
under the terms of SeraCare's Insurance Policies.

     Section 9.27   Liabilities.  "Liabilities" means all debts, liabilities,
                    -----------
guarantees, assurances, commitments, obligations and claims (including
reasonable attorneys' fees), whether fixed, contingent or absolute, asserted or
unasserted, matured or unmatured, liquidated or unliquidated, accrued or not
accrued, known or unknown, due or to become due, whenever or however arising
(including, without limitation, whether arising out of any contract, regulatory
requirement, court order or injunction, or tort based on negligence or strict
liability) and whether or not the same would be required by generally accepted
accounting principles to be reflected in financial statements or disclosed in
the notes thereto.  For this purpose, "Contract" means any contract, agreement,
lease, license, sales order, purchase order, instrument or other commitment that
is binding on any Person or any part of its property under applicable law.

     Section 9.28   Life Sciences.  "Life Sciences" has the meaning set forth in
                    -------------
the introductory paragraph hereof.

     Section 9.29   Life Sciences Business.  "Life Sciences Business" means the
                    ----------------------
business and operations of SeraCare currently operated as the Life Sciences
Plasma Division, including, without limitation, the business and organization
for the manufacturing, marketing and selling of therapeutic based blood plasma
products, diagnostic test kits, specialty plasma used for diagnostic purposes
and bulk materials, and shall not include the business of collecting blood
plasma.

     Section 9.30   Life Sciences Group  "Life Sciences Group" means Life
                    -------------------
Sciences and each Subsidiary of Life Sciences (if any) immediately after the
Separation Date, and each Person that becomes a Subsidiary of Life Sciences
after the Separation Date.

                                     -21-
<PAGE>

     Section 9.31   Merger.  "Merger" has the meaning set forth in the Recitals
                    ------
hereof.

     Section 9.32   Merger Agreement.  "Merger Agreement" has the meaning set
                    ----------------
forth in the Recitals hereof.

     Section 9.33   Noncompetition Territory.  "Noncompetition Territory" has
                    ------------------------
the meaning set forth in Section 4.1 hereof.

     Section 9.34   Option Plan.  "Option Plan" has the meaning set forth in
                    -----------
Section 3.1(c) hereof.

     Section 9.35   Party or Parties "Party" or "Parties" has the meaning set
                    ----------------
forth in the introductory paragraph hereof.

     Section 9.36   Person.  "Person" means an individual, a partnership, a
                    ------
corporation, a limited liability company, an association, a joint stock company,
a trust, a joint venture, an unincorporated organization and a governmental
entity or any department, agency or political subdivision thereof.

     Section 9.37   Products  "Products" has the meaning set forth in Section
                    --------
1.1 of the Supply Agreement.

     Section 9.38   Receiving Party.  "Receiving Party" means the non-owning
                    ---------------
party or recipient of the relevant Confidential Information

     Section 9.39   Record Date.  "Record Date" means the close of business on
                    -----------
the date to be determined by the Board of Directors of SeraCare as the record
date for determining the stockholders of SeraCare entitled to receive shares of
common stock of Life Sciences in the Distribution.

     Section 9.40   Separation.  "Separation" has the meaning set forth in the
                    ----------
Recitals hereof.

     Section 9.41   Separation Date.  "Separation Date" has the meaning set
                    ---------------
forth in Section 1.1 hereof.

     Section 9.42   SeraCare  "SeraCare" has the meaning set forth in the
                    --------
introductory paragraph hereof.

     Section 9.43   SeraCare Business.  "SeraCare Business" means any business
                    -----------------
of SeraCare other than the Life Sciences Business.

     Section 9.44   SeraCare Group.  "SeraCare Group" means SeraCare and each
                    --------------
Subsidiary of SeraCare (other than Life Sciences) immediately after the
Separation Date, and each Person that becomes a Subsidiary of SeraCare after the
Separation Date.

     Section 9.45   SeraCare Options.  "SeraCare Options" has the meaning set
                    ----------------
forth in Section 3.2(c) hereof.

                                     -22-
<PAGE>

     Section 9.46   SeraCare Protected Business.  "SeraCare Protected Business"
                    ---------------------------
has the meaning set forth in Section 4.1 hereof.

     Section 9.47   SeraCare Warrants.  "SeraCare Warrants" has the meaning set
                    -----------------
forth in Section 3.2(c) hereof.

     Section 9.48   Subsidiary.  "Subsidiary" means with respect to any
                    ----------
specified Person, any corporation, any limited liability company, any
partnership or other legal entity of which such Person or its Subsidiaries owns,
directly or indirectly, more than 50% of the stock or other equity interest
entitled to vote on the election of the members of the board of directors or
similar governing body.

     Section 9.49   Supply Agreement  "Supply Agreement" shall mean the Supply
                    ----------------
and Services Agreement attached hereto as Exhibit G.

     Section 9.50   Third Party.  "Third Party" means a Person other than
                    -----------
SeraCare, its Subsidiaries and their respective employees and Life Sciences, its
Subsidiaries and their respective employees

     Section 9.51   Transaction Agreements.  "Transaction Agreements" means the
                    ----------------------
Separation Agreement and the Ancillary Agreements.

                                     -23-
<PAGE>

          IN WITNESS WHEREOF, each of the parties has caused this Agreement to
be executed on its behalf by its officers thereunto duly authorized on the day
and year first above written.

SERACARE, INC.                          SERACARE LIFE SCIENCES, INC.

By:    /s/ Barry D. Plost               By:    /s/ Jerry L. Burdick
       ---------------------------             ----------------------------
Name:  Barry D. Plost                   Name:  Jerry L. Burdick
Title: Chief Executive Officer          Title: Executive Vice President

       [SIGNATURE PAGE TO MASTER SEPARATION AND DISTRIBUTION AGREEMENT]

                                     -24-
<PAGE>

                            Schedules and Exhibits
                            ----------------------

Schedules:
---------

Schedule 3.1(d)     Board of Directors

Schedule 3.1(e)     Other Actions

Exhibits:
--------

Exhibit A.  Certificate of the Secretary (SeraCare)

Exhibit B.  Certificate of the Secretary (Life Sciences)

Exhibit C.  Assignment and Assumption Agreement

Exhibit D.  Trademark License Agreement

Exhibit E.  Employee Matters Agreement

Exhibit F.  Tax Matters Agreement

Exhibit G.  Supply and Services Agreement

                                      -i-
<PAGE>

                                Schedule 3.1(d)
                                ---------------

                              Board of Directors

Barry Plost

Jerry Burdick

Samuel Anderson

M. Ezzat Jallad

Dr. Nelson Teng

Robert J. Cresci

Dr. Bernard Kasten

                                      -2-
<PAGE>

                                Schedule 3.1(e)
                                ---------------

                                 Other Actions
                                 -------------

1.   Reclassification Actions

     A.   Reclassification of the Books of SeraCare

          1.   On the books of SeraCare, Goodwill in Life Sciences will be
               reclassified to the Investment In Life Sciences account.

          2.   All intercompany accounts between Life Sciences and SeraCare,
               including any subsidiaries of SeraCare, will be reclassified to
               the Investment In Life Sciences account.

          3.   Earnings since acquisition of Life Sciences by SeraCare will be
               Equity adjusted on the books of SeraCare.

          4.   The amount of Investment In Life Sciences will be dividended and
               charged to paid in surplus on the books of SeraCare in connection
               with the spin off.

     B.   Reclassification of the Books of Life Sciences

          1.   All intercompany accounts with SeraCare and/or any subsidiary of
               SeraCare will be reclassified to Paid In Surplus.

2.   Quest's right to appoint a director to the Board of Directors of SeraCare
     shall be terminated.

3.   Life Sciences shall have amended and restated its Articles of Incorporation
     and its Bylaws in a form mutually satisfactory to Life Sciences and
     SeraCare.

4.   Life Sciences shall have increased its authorized capital stock to an
     amount sufficient to effect the Distribution.

5.   Life Sciences shall have obtained consents from the following individuals
     or entities:

     A.   Arthur Kazarian as trustee for the General Wood Investment Trust in
          connection with the Standard Industrial/Commercial Multi-Tennant
          Lease-Gross between Del Oro Gateway Partners, L.P. and The Western
          States Group Inc. dated as of April 16, 1998, and addendums attached
          thereto dated on or about October 12, 1998 and January 7, 1999, and
          assignment agreement dated ___, 2001 among Del Oro Gateway Partners,
          L.P. and Arthur Kazarian as trustee for the General Wood Investment
          Trust (Del Oro Gateway Commerce Centre, 1935 Avenida del Oro, Suite F,
          Oceanside, California).

                                      -3-
<PAGE>

6.   Life Sciences shall have taken appropriate action to have its Common Stock
     traded on the OTC Bulletin Board.

                                      -4-<PAGE>

                                                                    EXHIBIT 10.9

                                                                      Exhibit C

                  GENERAL ASSIGNMENT AND ASSUMPTION AGREEMENT

                                    BETWEEN

                                SERACARE, INC.

                                      AND

                         SERACARE LIFE SCIENCES, INC.

                                 June 10, 2001
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                                   Page

<S>                                                                                                                <C>
                                                      ARTICLE I

                                        CONTRIBUTION, TRANSFER AND ASSUMPTION

Section 1.1       Contribution of Assets and Assumption of Liabilities..........................................      1
Section 1.2       Life Sciences Assets..........................................................................      2
Section 1.3       Life Sciences Liabilities.....................................................................      3
Section 1.4       Methods of Transfer And Assumption............................................................      4
Section 1.5       Governmental Approvals and Consents for Transfer of Life Sciences Assets......................      6
Section 1.6       Nonrecurring Costs and Expenses...............................................................      6
Section 1.7       Novation of Assumed Life Sciences Liabilities.................................................      7
Section 1.8       Transfer of Domain Name.......................................................................      7

                                                      ARTICLE II

                                                      LITIGATION

Section 2.1       Allocation....................................................................................      8
Section 2.2       Cooperation...................................................................................      9

                                                     ARTICLE III

                                               MISCELLANEOUS PROVISIONS

Section 3.1       LIMITATION OF LIABILITY.......................................................................      9
Section 3.2       Entire Agreement..............................................................................      9
Section 3.3       Dispute Resolution............................................................................      9
Section 3.4       Governing Law.................................................................................     10
Section 3.5       Notices.......................................................................................     10
Section 3.6       Counterparts..................................................................................     10
Section 3.7       Binding Effect; Assignment....................................................................     10
Section 3.8       Severability..................................................................................     10
Section 3.9       Waiver of Breach..............................................................................     10
Section 3.10      Amendment and Execution.......................................................................     11
Section 3.11      Authority.....................................................................................     11
Section 3.12      Descriptive Headings..........................................................................     11
Section 3.13      Gender and Number.............................................................................     11
Section 3.14      Additional Assurances.........................................................................     11
Section 3.15      Force Majeure.................................................................................     11
Section 3.16      Conflicting Agreements........................................................................     11
Section 3.17      Termination...................................................................................     12
Section 3.18      Survival......................................................................................     12
Section 3.19      Third Party Beneficiary.......................................................................     12
Section 3.20      Additional Representations and Warranties.....................................................     12
</TABLE>

                                      -i-
<PAGE>

                               TABLE OF CONTENTS
                                  (continued)

<TABLE>
<CAPTION>
                                                                                                                   Page

<S>                                                                                                                <C>
                                                      ARTICLE IV

                                                     DEFINITIONS

Section 4.1       Ancillary Agreement...........................................................................     12
Section 4.2       Assets........................................................................................     12
Section 4.3       Consent.......................................................................................     13
Section 4.4       Contract......................................................................................     13
Section 4.5       Disputes......................................................................................     14
Section 4.6       Distribution..................................................................................     14
Section 4.7       Distribution Date.............................................................................     14
Section 4.8       Excluded Assets...............................................................................     14
Section 4.9       Excluded Liabilities..........................................................................     14
Section 4.10      Governmental Approvals........................................................................     14
Section 4.11      Governmental Authority........................................................................     14
Section 4.12      Insurance Policies............................................................................     14
Section 4.13      Insured Life Sciences Liability...............................................................     14
Section 4.14      Intellectual Property.........................................................................     14
Section 4.15      Liabilities...................................................................................     14
Section 4.16      Life Sciences Assets..........................................................................     15
Section 4.17      Life Sciences Balance Sheet...................................................................     15
Section 4.18      Life Sciences Business........................................................................     15
Section 4.19      Life Sciences Contingent Claim................................................................     15
Section 4.20      Life Sciences Contingent Liability............................................................     15
Section 4.21      Life Sciences Contracts.......................................................................     15
Section 4.22      Life Sciences Group...........................................................................     16
Section 4.23      Life Sciences Liabilities.....................................................................     16
Section 4.24      Merger........................................................................................     16
Section 4.25      Person........................................................................................     16
Section 4.26      Security Interest.............................................................................     16
Section 4.27      Separation....................................................................................     16
Section 4.28      Separation Agreement..........................................................................     16
Section 4.29      Separation Date...............................................................................     16
Section 4.30      SeraCare Business.............................................................................     16
Section 4.31      SeraCare Group................................................................................     16
Section 4.32      Subsidiary....................................................................................     16
Section 4.33      Trademark License Agreement...................................................................     17
Section 4.34      Transferred Litigation........................................................................     17
</TABLE>

                                     -ii-
<PAGE>

                                   SCHEDULES

         SCHEDULE 1.2(a)     Assets Listed on the Life Sciences Balance Sheet

         SCHEDULE 1.3(a)     Included Liabilities

         SCHEDULE 1.3(b)     Excluded Liabilities

         SCHEDULE 2.1(a)     Transferred Litigation

         SCHEDULE 2.1(b)     Excluded Litigation

         SCHEDULE 4.30       Material Contracts
<PAGE>

                  GENERAL ASSIGNMENT AND ASSUMPTION AGREEMENT

     This General Assignment and Assumption Agreement (this "Agreement") is
entered into on June 10, 2001 between SeraCare, Inc., a Delaware corporation
("SeraCare"), and SeraCare Life Sciences, Inc., a California corporation ("Life
Sciences"). Capitalized terms used herein and not otherwise defined herein shall
have the meanings ascribed to such terms in Article IV hereof. SeraCare and Life
Sciences are sometimes referred to herein collectively as the "parties" or
individually as a "party."

                                   RECITALS

     WHEREAS, SeraCare hereby and by certain other instruments of even date
herewith transfers or will transfer to Life Sciences effective as of the
Separation Date, substantially all of the business and assets of the Life
Sciences Business owned by SeraCare in accordance with the Separation Agreement.
It is the intent of the parties hereto, by this Agreement and the other
agreements and instruments provided for in the Separation Agreement, that
SeraCare and its Subsidiaries convey to Life Sciences substantially all of the
business and assets of the Life Sciences Business not presently owned by Life
Sciences; and

     WHEREAS, it is further intended between the parties that Life Sciences
assume all of the liabilities related to the Life Sciences Business, as provided
in this Agreement, the Separation Agreement or the other agreements and
instruments provided for in the Separation Agreement.

     NOW, THEREFORE, in consideration of the foregoing and the covenants and
agreements set forth below, the parties hereto agree as follows:

                                   ARTICLE I
                     CONTRIBUTION, TRANSFER AND ASSUMPTION

     Section 1.1  Contribution of Assets and Assumption of Liabilities.
                  ----------------------------------------------------

     (a)  Transfer of Assets.  Effective on the Separation Date, SeraCare hereby
          ------------------
assigns, transfers, conveys and delivers to Life Sciences, and Life Sciences
hereby accepts from SeraCare, all of SeraCare's right, title and interest in all
the Life Sciences Assets.

     (b)  Assumption of Liabilities.  Effective on the Separation Date, Life
          -------------------------
Sciences hereby assumes and agrees faithfully to perform and fulfill all the
Life Sciences Liabilities, in accordance with their respective terms, and
undertakes to pay, satisfy and discharge when due all the Life Sciences
Liabilities in accordance with their terms.

     (c)  Misallocated Assets. In the event that at any time or from time to
          -------------------
time (whether prior to or after the Separation Date), any party hereto (or any
member of the SeraCare Group) shall receive or otherwise possess any Asset that
is allocated to any other Person pursuant to this Agreement or any other
Ancillary Agreement, such party shall promptly transfer, or cause to be
<PAGE>

transferred, such Asset to the Person so entitled thereto. Prior to any such
transfer, the Person receiving or possessing such Asset shall hold such Asset in
trust for any such other Person entitled to such Asset.

     Section 1.2  Life Sciences Assets.
                  --------------------

     (a)  Included Assets.  For purposes of this Agreement, "Life Sciences
          ---------------
Assets" shall mean (without duplication) the following Assets, except as
otherwise provided for herein or in any Ancillary Agreement or other express
agreement of the parties:

          (i)    all Assets listed in the Life Sciences Balance Sheet and set
forth on Schedule 1.2(a), subject to any dispositions of such Assets subsequent
to the date of the Life Sciences Balance Sheet;

          (ii)   all Assets acquired by SeraCare or its Subsidiaries after the
date of the Life Sciences Balance Sheet used primarily in the Life Sciences
Business and that would be reflected in a balance sheet of Life Sciences as of
the Separation Date if (A) such balance sheet was prepared using the same
principles and accounting policies under which the Life Sciences Balance Sheet
was prepared, and (B) SeraCare and Life Sciences had conducted their respective
businesses in the ordinary course since the date of the Life Sciences Balance
Sheet;

          (iii)  all Life Sciences Contingent Claims;

          (iv)   all Life Sciences Contracts;

          (v)    all Assets, whether arising before, on or after the Separation
Date, primarily relating to, arising out of or resulting from any Life Sciences
Liabilities (including, without limitation, the indemnification rights relating
to the Life Sciences business in favor of SeraCare in the Stock Purchase
Agreement dated February 13, 1998 among SeraCare, Inc., The Western States
Group, Inc., Michael Crowley, and individual, Mary Crowley, an individual,
Michael F. Crowley, Mary A. Crowley as trustees under the Crowley Charitable
Remainder Unitrust dated December 31, 1997 and Michael F. Crowley II);

          (vi)   to the extent permitted by law and subject to the Separation
Agreement and the Ancillary Agreements, all rights of Life Sciences under any of
SeraCare's Insurance Policies or other insurance policies issued by Persons
unaffiliated with SeraCare;

          (vii)  all legal and equitable remedies associated with the
Transferred Litigation;

          (viii) all Assets that are expressly contemplated by this Agreement,
the Separation Agreement or any other Ancillary Agreement (or any other Schedule
hereto or thereto) as Assets to be transferred to Life Sciences;

          (ix)   the rights in and to the name "SeraCare" set forth in the
Trademark License Agreement;

          (x)    the rights in and to the domain name "SeraCare.net" as set
forth in Section 1.8; and

                                      -2-
<PAGE>

          (xi)   the rights to three advertisements in Canon Communications LLC
magazine, IVD Technology in connection with the June 5, 2001 settlement
agreement referenced in Item 1 to Schedule 2.1(a).

     Notwithstanding the foregoing, the Life Sciences Assets shall not in any
event include the Excluded Assets referred to in Section 1.2(b) below.

     (b)  Excluded Assets. For the purposes of this Agreement, "Excluded Assets"
          ---------------
shall mean any Assets (i) used by the parties in the business of the collection
of blood plasma, (ii) certain advances to Western States employees in the amount
of $58,900, and (iii) any other Assets that are expressly contemplated by the
Separation Agreement, this Agreement or any other Ancillary Agreement (or the
Schedules hereto or thereto) as Assets to be retained by SeraCare or any other
member of the SeraCare Group (collectively, the "SeraCare Assets").  For the
avoidance of doubt, the parties intend and agree that any Assets, other than the
Life Sciences Assets, owned or used by the SeraCare Group and Life Sciences on
the date hereof, shall be deemed to be Excluded Assets and shall be retained by
SeraCare hereunder.

     Section 1.3  Life Sciences Liabilities.
                  -------------------------

     (a)  Included Liabilities. For the purposes of this Agreement, "Life
          --------------------
Sciences Liabilities" shall mean (without duplication) the following
Liabilities, except as otherwise provided for in any Ancillary Agreement or
other express agreement of the parties:

          (i)    all Liabilities reflected in the Life Sciences Balance Sheet,
to the extent such Liabilities have not been satisfied or discharged subsequent
to the date of the Life Sciences Balance Sheet;

          (ii)   all Liabilities of SeraCare or its Subsidiaries that arise
after the date of the Life Sciences Balance Sheet relating primarily to the Life
Sciences Business that would be reflected in a balance sheet of Life Sciences
dated as of the Separation Date if (A) such balance sheet was prepared using the
same principles and accounting policies under which the Life Sciences Balance
Sheet was prepared and (B) SeraCare and Life Sciences had conducted their
respective businesses in the ordinary course since the date of the Life Sciences
Balance Sheet;

          (iii)  all Life Sciences Contingent Liabilities;

          (iv)   except as otherwise expressly contemplated by this Agreement,
the Separation Agreement or any other Ancillary Agreement, all Liabilities,
whether arising before, on or after the Separation Date, primarily relating to,
arising out of or resulting from:

                 (1) the operation of the Life Sciences Business, as conducted
at any time prior to, on or after the Separation Date, or

                 (2) any Life Sciences Assets;

          (v)    all Liabilities that are expressly contemplated by this
Agreement, the Separation Agreement or any other Ancillary Agreement (or the
Schedules hereto or thereto) as Liabilities to be assumed by Life Sciences,
including liabilities set forth on Schedule 1.3(a);

                                      -3-
<PAGE>

          (vi)   all obligations and Liabilities of Life Sciences under the
Separation Agreement, this Agreement or any of the other Ancillary Agreements;
and

          (vii)  all Liabilities arising out of the Form 10 Registration
Statement filed by Life Sciences with the Securities and Exchange Commission and
the Information Statement mailed prior to the Distribution Date to the holders
of Common Stock of SeraCare.

     Notwithstanding the foregoing, the Life Sciences Liabilities shall not
include the Excluded Liabilities referred to in Section 1.3(b) below.

     (b)  Excluded Liabilities.  For the purposes of this Agreement, "Excluded
          --------------------
Liabilities" shall mean:

          (i)    the Liabilities listed on Schedule 1.3(b) hereto;

          (ii)   all Insured Life Sciences Liabilities, provided, however if
SeraCare's insurance carrier fails to make a payment when due with respect to a
claim relating to a Life Sciences Liability, then upon written notice from
SeraCare, Life Sciences shall make an interim payment to SeraCare, provided
further, that if such interim payment is made, SeraCare shall immediately assign
to Life Sciences its right to recover such claim from its insurance carrier (to
the extent of the interim payment received by SeraCare pursuant to this Section
1.3(b)(ii)), and if payment for such claim is nonetheless made directly to
SeraCare, SeraCare shall immediately turn over the proceeds from such claim to
Life Sciences (to the extent of the interim payment received by SeraCare
pursuant to this Section 1.3(b)(ii));

          (iii)  all Liabilities that are expressly contemplated by this
Agreement, the Separation Agreement or any other Ancillary Agreement (or the
Schedules hereto or thereto) as Liabilities to be retained or assumed by
SeraCare or any other member of the SeraCare Group, and all agreements and
obligations of any member of the SeraCare Group under the Separation Agreement,
this Agreement or any other Ancillary Agreement.

     Section 1.4  Methods of Transfer And Assumption.
                  ----------------------------------

     (a)  Terms of Other Ancillary Agreements Govern.  The parties shall enter
          ------------------------------------------
into the other Ancillary Agreements, on or about the date of this Agreement.
Except as set forth herein, it is the intent of the parties that pursuant to
Section 1.1, Section 1.2, and Section 1.3, the transfer and assumption of all
other Life Sciences Assets and Life Sciences Liabilities shall be made effective
as of the Separation Date.

     (b)  Mistaken Assignments and Assumptions.  In addition to those transfers
          ------------------------------------
and assumptions accurately identified and designated by the parties to take
place but which the parties are not able to effect prior to the Separation Date,
there may exist (i) Assets that the parties discover were, contrary to the
agreements between the parties, by mistake or omission, transferred to Life
Sciences or retained by SeraCare or Life Sciences (ii) Liabilities that the
parties discover were, contrary to the agreements between the parties, by
mistake or omission, assumed by Life Sciences or not assumed by Life Sciences.
The parties shall cooperate in good faith to effect the transfer or re-transfer
of such Assets, and/or the assumption or re-assumption of such Liabilities, to
or by the appropriate party and shall not use the determination that

                                      -4-
<PAGE>

remedial actions need to be taken to alter the original intent of the parties
hereto with respect to the Assets to be transferred to or Liabilities to be
assumed by Life Sciences or SeraCare. Each party shall reimburse the other or
make other financial adjustments (e.g., without limitation, cash reserves) or
other adjustments to remedy any improper transfer or failure to transfer any
Asset or any improper assumption or failure to assume any Liability.

     (c)  Transfer of Assets and Liabilities Not Included in Life Sciences
          ----------------------------------------------------------------
Assets and Life Sciences Liabilities. Except as otherwise expressly provided in
------------------------------------
this Agreement, the Separation Agreement or any other Ancillary Agreement, in
the event the parties discover Assets and Liabilities that relate primarily to
the Life Sciences Business but do not constitute Life Sciences Assets under
Section 1.2 or Life Sciences Liabilities under Section 1.3, the parties shall
cooperate in good faith to effect the transfer of such Assets at book value, or
the assumption of such Liabilities, to or by Life Sciences or its Subsidiaries
and shall not use the determination of remedial actions contemplated in the
Separation Agreement to alter the original intent of the parties hereto with
respect to the Assets to be transferred to or Liabilities to be assumed by Life
Sciences. Except as otherwise expressly provided in this Agreement, the
Separation Agreement or any other Ancillary Agreement, in the event the parties
discover Assets or Liabilities that relate primarily to the SeraCare Business
but do not constitute Assets of the SeraCare Business by operation of Section
1.2 or Liabilities of the SeraCare Business by operation of Section 1.3, the
parties shall cooperate in good faith to effect the transfer of such Assets at
book value, or the assumption of such Liabilities, to or by the SeraCare Group
or its Subsidiaries and shall not use the determination of remedial actions
contemplated in the Separation Agreement to alter the original intent of the
parties hereto with respect to the Assets or Liabilities to be retained by the
SeraCare Group. Each party shall reimburse the other or make other financial
adjustments (e.g., without limitation, cash reserves) or other adjustments to
remedy any improper transfer or failure to transfer any Asset or any improper
assumption or failure to assume any Liability.

     (d)  Documents Relating to Other Transfers of Assets and Assumption of
          -----------------------------------------------------------------
Liabilities.
-----------

          (i)    In furtherance of the assignment, transfer, conveyance and
delivery of Life Sciences Assets and the assumption of Life Sciences Liabilities
set forth in Section 1.4 (a), (b) or (c), effective as of the Separation Date,
(i) the members of the SeraCare Group shall execute and deliver such bills of
sale, stock powers, certificates of title, assignments of contracts and other
instruments of transfer, conveyance and assignment as and to the extent
necessary to evidence the transfer, conveyance and assignment of all of
SeraCare's and its Subsidiaries' right, title and interest in and to the Life
Sciences Assets to Life Sciences and (ii) Life Sciences shall execute and
deliver to SeraCare and its Subsidiaries such assumptions of contracts and other
instruments of assumption as and to the extent necessary to evidence the valid
and effective assumption of the Life Sciences Liabilities by Life Sciences.

          (ii)   In furtherance of the assignment, transfer, conveyance and
delivery of Assets to the SeraCare Group and the assumption of Liabilities by
the SeraCare Group by the operation of Section 1.4(a), (b) or (c), effective as
of the Separation Date, (i) Life Sciences shall execute and deliver such bills
of sale, stock powers, certificates of title, assignments of contracts and other
instruments of transfer, conveyance and assignment as and to the extent
necessary to evidence the transfer, conveyance and assignment of all the right,
title and interest of Life Sciences and its Subsidiaries in and to the Assets of
the SeraCare Group and (ii) the SeraCare

                                      -5-
<PAGE>

Group shall execute and deliver to Life Sciences and its Subsidiaries such
assumptions of contract and other instruments of assumption as and to the extent
necessary to evidence the valid and effective assumption of the Liabilities of
the SeraCare Group by the SeraCare Group.

     Section 1.5  Governmental Approvals and Consents for Transfer of Life
                  --------------------------------------------------------
Sciences Assets.
---------------

     (a)  Transfer in Violation of Laws.  If and to the extent that the valid,
          -----------------------------
complete and perfected transfer, assignment or novation to Life Sciences of any
Life Sciences Asset would be a violation of applicable laws or require any
Consent or Governmental Approval in connection with the Separation or the
Distribution, then, unless SeraCare shall otherwise determine, the transfer,
assignment or novation to Life Sciences, as the case may be, of any of such Life
Sciences Assets automatically shall be deemed deferred and any such purported
transfer, assignment or novation shall be null and void until such time as all
legal impediments are removed and/or such Consents or Governmental Approvals
have been obtained; provided, however, that if any such Consent or Governmental
Approval has not been obtained within six months of the Distribution Date, the
parties will use their reasonable commercial efforts to achieve an alternative
solution in accordance with the parties' intentions.  If any such Consent shall
not be obtained, SeraCare shall cooperate with Life Sciences in any reasonable
arrangement designed to provide for Life Sciences the benefits intended to be
assigned to Life Sciences under the relevant contract, license or other
instrument, including enforcement at the cost and for the account of Life
Sciences of any and all rights of SeraCare against the other party thereto
arising out of the breach or cancellation thereof by such other party or
otherwise.

     (b)  Transfers Not Consummated Prior to Separation Date.  If the transfer,
          --------------------------------------------------
assignment or novation of any Assets intended to be transferred or assigned
hereunder is not consummated prior to or on the Separation Date, whether as a
result of the provisions of Section 1.5(a) or for any other reason, then the
Person retaining such Asset shall thereafter hold such Asset for the use and
benefit, insofar as reasonably possible, of the Person entitled thereto (at the
expense of the Person entitled thereto).  In addition, the Person retaining such
Asset shall take such other actions as may be reasonably requested by the Person
to whom such Asset is to be transferred in order to place such Person, insofar
as reasonably possible, in the same position as if such Asset had been
transferred as contemplated hereby and so that all the benefits and burdens
relating to such Assets, including possession, use, risk of loss, potential for
gain, and dominion, control and command over such Assets, are to inure from and
after the Separation Date to the Person entitled to such Assets.  If and when
the Consents and/or Governmental Approvals, the absence of which caused the
deferral of transfer of any Asset pursuant to Section 1.5(a), are obtained, the
transfer of the applicable Asset shall be effected in accordance with the terms
of this Agreement and/or the applicable Ancillary Agreement.

     (c)  Expenses.  The Person retaining an Asset due to the deferral of the
          --------
transfer of such Asset shall not be obligated, in connection with the foregoing,
to expend any money unless the necessary funds are advanced by the Person
entitled to the Asset, other than reasonable out-of-pocket expenses, attorneys'
fees and recording or similar fees, all of which shall be promptly reimbursed by
the Person entitled to such Asset.

                                      -6-
<PAGE>

     Section 1.6  Nonrecurring Costs and Expenses.  Notwithstanding anything
                  -------------------------------
herein to the contrary, any nonrecurring costs and expenses incurred by the
parties hereto to effect the transactions contemplated hereby which are not
allocated pursuant to the terms of the Separation Agreement, this Agreement or
any other Ancillary Agreement shall be the responsibility of the party to whom
such costs and expenses are attributable.

     Section 1.7  Novation of Assumed Life Sciences Liabilities.
                  ---------------------------------------------

     (a)  Reasonable Commercial Efforts.  Each of SeraCare and Life Sciences,
          -----------------------------
at the request of the other, shall use its reasonable commercial efforts to
obtain, or to cause to be obtained, any Consent, Government Approval,
substitution or amendment required to effect a novation of or assign all rights
and obligations under agreements, leases, licenses and other obligations or
Liabilities of any nature whatsoever that constitute Life Sciences Liabilities
or to obtain in writing the unconditional release of all parties to such
arrangements other than Life Sciences, so that, in any such case, Life Sciences
and its Subsidiaries will be solely responsible for such Liabilities; provided,
however, that neither SeraCare, Life Sciences nor their Subsidiaries shall be
obligated to pay any consideration therefor to any third party from whom such
Consents, Government Approvals, substitutions and amendments are requested.
Notwithstanding anything to the contrary in the Separation Agreement or any of
the Ancillary Agreements, the former officers and employees of SeraCare and the
present officers, directors and employees of Life Sciences do not release
SeraCare from any indemnification obligations it may have to them arising from
Delaware or California law, SeraCare's Bylaws or Certificate of Incorporation or
which arise by contract by operation of law or otherwise and Life Sciences shall
have no obligation to use any effort to obtain or cause to be obtained any
novation or assignment of such agreements, obligations or liabilities of
SeraCare.

     (b)  Inability to Obtain Novation. If SeraCare or Life Sciences is unable
          ----------------------------
to obtain, or to cause to be obtained, any such required Consent, Government
Approval, release, substitution or amendment, the applicable member of the
SeraCare Group shall continue to be bound by such agreements, leases, licenses
and other obligations and, unless not permitted by law or the terms thereof
(except to the extent expressly set forth in this Agreement, the Separation
Agreement or any other Ancillary Agreement), Life Sciences shall, as agent or
subcontractor for SeraCare or such other Person, as the case may be, pay,
perform and discharge fully, or cause to be paid, transferred or discharged all
the obligations or other Liabilities of SeraCare or such other Person, as the
case may be, thereunder from and after the date hereof. SeraCare shall, without
further consideration, pay and remit, or cause to be paid or remitted, to Life
Sciences or its appropriate Subsidiary promptly all money, rights and other
consideration received by it or any member of the SeraCare Group in respect of
such performance (unless any such consideration is an Excluded Asset). If and
when any such Consent, Government Approval, release, substitution or amendment
shall be obtained or such agreement, lease, license or other rights or
obligations shall otherwise become assignable or able to be novated, SeraCare
shall thereafter assign, or cause to be assigned, all its rights, obligations
and other Liabilities thereunder or any rights or obligations of any member of
the SeraCare Group to Life Sciences without payment of further consideration and
Life Sciences shall, without the payment of any further consideration, assume
such rights and obligations.

     Section 1.8  Transfer of Domain Name
                  -----------------------

                                      -7-
<PAGE>

     (a)  Effective as of the Separation Date, SeraCare shall, sell, transfer,
convey and assign to Life Sciences, free and clear of any and all liens,
security interests, claims and encumbrances, the Internet domain name
"SeraCare.net" (the "Domain Name").  Accordingly, at the Separation Date,
SeraCare shall transfer to Life Sciences all of the domain name registrations
for the Domain Name which are registered at any Internet domain name
registration authorities, including, without limitation, the Network Solutions
and/or Register.com registration of the Domain Name.

     (b)  From time to time after the Separation Date, SeraCare shall execute
and deliver to Life Sciences such instruments of transfer and other instruments,
including, without limitation, the Network Solutions Registrant Name Change
Agreement Transfer Agreement attached hereto as Exhibit B (the "Transfer
                                                ---------
Agreement"), as may be reasonably requested by Life Sciences in order to vest in
Life Sciences good and marketable title in and to the Domain Name and otherwise
in order to carry out the purpose and intent of this Section 1.8.  SeraCare and
covenants not to bring any claim against Life Sciences for any infringement of
SeraCare's intellectual property rights for any use by Life Sciences of the
Domain Name.

                                  ARTICLE II
                                  LITIGATION

     Section 2.1  Allocation.
                  ----------

     (a)  Litigation to Be Transferred to Life Sciences. On the Separation Date,
          ---------------------------------------------
the responsibilities for management of the litigation identified in Schedule 2.1
shall be transferred in their entirety from SeraCare and its Subsidiaries to
Life Sciences (the "Transferred Litigation").  Effective as of the Separation
Date, SeraCare hereby assigns to Life Sciences all right, title and interest in
and to the Transferred Litigation, including without limitation all claims and
causes of action asserted by or to be asserted by SeraCare and/or Life Sciences
in the Transferred Litigation and all remedies, whether in law or equity,
associated therewith, including the exclusive right to retain any settlement,
judgment or any other amounts paid or other benefits received in respect of such
Transferred Litigation.  Effective as of the Separation Date, SeraCare agrees
that Life Sciences shall have the exclusive right to prosecute the Transferred
Litigation in the name of SeraCare, and SeraCare agrees to sign documents
reasonably requested by Life Sciences during the course of the litigation,
including documents relating to settlement and release of claims.  As of the
Separation Date and thereafter, Life Sciences shall manage this litigation at
its sole discretion and shall be solely responsible for all costs and fees
incurred in connection therewith and shall be entitled to retain any and all
sums recovered in connection therewith whether by settlement, judgment or
otherwise, and Life Sciences shall have sole and absolute discretion with
respect to settlement, disposition, compromise or other resolution.  Except as
provided herein, Life Sciences agrees that it shall make appropriate
arrangements so that any legal fees or other expenses related to the Transferred
Litigation shall be the sole obligation of Life Sciences.  SeraCare and its
Subsidiaries must first obtain the prior consent of Life Sciences for any action
taken subsequent to the Separation Date in connection with the Transferred
Litigation, which consent may not be unreasonably withheld or delayed.

                                      -8-
<PAGE>

     (b)  Other Litigation.  Except as specifically provided on Schedule 2.1(b),
          ----------------
(i) Life Sciences agrees that as of the date hereof it shall be solely
responsible for the management and all Liabilities, costs and expenses
(including without limitation all attorneys' fees and expenses) in respect of
any litigation that primarily relates to or results from the Life Sciences
Business and the SeraCare Group shall have no liability or responsibility in
respect of such litigation, and (ii) SeraCare agrees that as of the date hereof
it shall be solely responsible for the management and all liabilities, costs and
expenses (including without limitation all attorneys' fees and expenses) in
respect of any litigation that primarily relates to or results from the SeraCare
Business and the Life Sciences Group shall have no liability or responsibility
in respect of such litigation, whether or not the facts or events giving rise to
such litigation occur on or before the date hereof.

     Section 2.2  Cooperation.  SeraCare and Life Sciences and their respective
                  -----------
Subsidiaries shall cooperate with each other in the prosecution and defense of
any litigation covered under this Article II and afford to each other reasonable
access upon reasonable advance notice to witnesses and information (other than
information protected from disclosure by applicable privileges) that is
reasonably required to prosecute or defend such litigation as set forth in
Article VII of the Separation Agreement.  The foregoing agreement to cooperate
includes, but is not limited to, an obligation to provide access to qualified
assistance to provide information, witnesses and documents to respond to
discovery requests in specific lawsuits.  In such cases, cooperation shall be
timely so that the party responding to discovery may meet all court-imposed
deadlines.  The party requesting information shall reimburse the party providing
information consistent with the terms of Article VII of the Separation
Agreement.  The obligations set forth in this paragraph are more clearly defined
in Article VII of the Separation Agreement, to which reference is hereby made.

                                  ARTICLE III
                           MISCELLANEOUS PROVISIONS

     Section 3.1  LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY OR ITS
                  -----------------------
SUBSIDIARIES BE LIABLE TO THE OTHER PARTY OR ITS SUBSIDIARIES FOR ANY SPECIAL,
CONSEQUENTIAL, INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS, HOWEVER
CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY WAY
OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH OTHER PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES.

     Section 3.2  Entire Agreement.  This Agreement, the Separation Agreement,
                  ----------------
the other Ancillary Agreements and the Exhibits and Schedules referenced or
attached hereto and thereto, constitute the entire agreement between the parties
with respect to the subject matter hereof and shall supersede all prior written
and oral and all contemporaneous oral agreements and understandings with respect
to the subject matter hereof.

     Section 3.3  Dispute Resolution.  Any and all controversies, disputes or
                  ------------------
claims arising out of, relating to, in connection with or resulting from this
Agreement (or any amendment thereto or any transaction contemplated hereby or
thereby), including as to its existence, interpretation, performance, non-
performance, validity, breach or termination, including any claim based on
contract, tort, statute or constitution and any claim raising questions of law,

                                      -9-
<PAGE>

whether arising before or after termination of this Agreement, shall be deemed a
Dispute as defined in Section 7.6 of the Separation Agreement and shall be
resolved exclusively by, in accordance with, and subject to the limitations set
forth in Section 7.6 of the Separation Agreement.

     Section 3.4  Governing Law. This Agreement shall be construed in accordance
                  -------------
with and all Disputes hereunder shall be governed by the laws of the State of
California, excluding its conflict of law rules.

     Section 3.5  Notices.  Any notice, demand, offer, request or other
                  -------
communication required or permitted to be given by either party pursuant to the
terms of this Agreement shall be in writing and shall be deemed effectively
given the earlier of (i) when received, (ii) when delivered personally, (iii)
one (1) business day after being delivered by facsimile (with receipt of
appropriate confirmation), (iv) one (1) business day after being deposited with
an overnight courier service, or (v) four (4) days after being deposited in the
U.S. mail, First Class with postage prepaid, and addressed to the attention of
the party's Chief Executive Officer at the address of its principal executive
office or such other address as a party may request by notifying the other party
thereof in writing.

     Section 3.6  Counterparts.  This Agreement, including the Schedules hereto
                  ------------
and the other documents referred to herein, may be executed in counterparts via
facsimile or otherwise, each of which shall be deemed to be an original but all
of which shall constitute one and the same agreement.

     Section 3.7  Binding Effect; Assignment.  This Agreement shall inure to the
                  --------------------------
benefit of and be binding upon the parties hereto and their respective legal
representatives and successors, and nothing in this Agreement, express or
implied, is intended to confer upon any other Person any rights or remedies of
any nature whatsoever under or by reason of this Agreement.  Except as herein
specifically provided to the contrary, neither party may assign this Agreement
or any rights or obligations hereunder, without the prior written consent of the
other party, and any such assignment shall be void; provided, however, either
party (or its permitted successive assignees or transferees hereunder) may
assign or transfer this Agreement as a whole without consent to an entity that
succeeds to all or substantially all of the business or assets of such party to
which this Agreement relates.

     Section 3.8  Severability.  The parties hereto have negotiated and prepared
                  ------------
the terms of this Agreement in good faith with the intent that each and every
one of the terms, covenants and conditions herein be binding upon and inure to
the benefit of the respective parties.  Accordingly, if any one or more of the
terms, provisions, promises, covenants or conditions of this Agreement or the
application thereof to any person or circumstance shall be adjudged to any
extent invalid, unenforceable, void or voidable for any reason whatsoever by a
court of competent jurisdiction, such provision shall be as narrowly construed
as possible, and each and all of the remaining terms, provisions, promises,
covenants and conditions of this Agreement or their application to other persons
or circumstances shall not be affected thereby and shall be valid and
enforceable to the fullest extent permitted by law.  To the extent this
Agreement is in violation of applicable law, then the parties agree to negotiate
in good faith to amend the Agreement, to the extent possible consistent with its
purposes, to conform to law.

                                     -10-
<PAGE>

     Section 3.9  Waiver of Breach.  The waiver by either party hereto of a
                  ----------------
breach or violation of any provision of this Agreement shall not operate as, or
be construed to constitute, a waiver of any subsequent breach of the same or
another provision hereof.

     Section 3.10 Amendment and Execution.  This Agreement and amendments hereto
                  -----------------------
shall be in writing and executed in multiple copies via facsimile or otherwise
on behalf of SeraCare and Life Sciences by their respective duly authorized
officers and representatives.  Each multiple copy shall be deemed an original,
but all multiple copies together shall constitute one and the same instrument.
The parties hereto agree that this Agreement shall not be amended or modified
without the express written consent of Instituto Grifols, S.A., which consent
shall not be unreasonably withheld or delayed.

     Section 3.11 Authority.  Each of the parties hereto represents to the other
                  ---------
that (a) it has the corporate or other requisite power and authority to execute,
deliver and perform this Agreement, (b) the execution, delivery and performance
of this Agreement by it have been duly authorized by all necessary corporate or
other actions, (c) it has duly and validly executed and delivered this
Agreement, and (d) this Agreement is a legal, valid and binding obligation,
enforceable against it in accordance with its terms subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting creditors' rights generally and general equity principles.

     Section 3.12 Descriptive Headings. The headings contained in this
                  --------------------
Agreement, in any Exhibit or Schedule hereto and in the table of contents to
this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement. Any capitalized term used in
any Schedule or Exhibit but not otherwise defined therein, shall have the
meaning assigned to such term in this Agreement. When a reference is made in
this Agreement to an Article or a Section, Exhibit or Schedule, such reference
shall be to an Article or Section of, or an Exhibit or Schedule to, this
Agreement unless otherwise indicated.

     Section 3.13 Gender and Number.  Whenever the context of this Agreement
                  -----------------
requires, the gender of all words herein shall include the masculine, feminine
and neuter, and the number of all words herein shall include the singular and
plural.

     Section 3.14 Additional Assurances.  Except as may be specifically provided
                  ---------------------
herein to the contrary, the provisions of this Agreement shall be self-operative
and shall not require further agreement by the parties; provided, however, at
the request of either party, the other party shall execute such additional
instruments and take such additional acts as are reasonable, and as the
requesting party may reasonably deem necessary, to effectuate this Agreement.

     Section 3.15 Force Majeure.  Neither party shall be liable or deemed to be
                  -------------
in default for any delay or failure in performance under this Agreement or other
interruption of service deemed to result, directly or indirectly, from acts of
God, civil or military authority, acts of public enemy, war, accidents,
explosions, earthquakes, floods, failure of transportation, strikes or other
work interruptions by either party's employees, or any other similar cause
beyond the reasonable control of either party unless such delay or failure in
performance is expressly addressed elsewhere in this Agreement.

                                     -11-
<PAGE>

     Section 3.16 Conflicting Agreements.  In the event of conflict between this
                  ----------------------
Agreement and any other Ancillary Agreement or other agreement executed in
connection herewith, the provisions of such other agreement shall prevail.

     Section 3.17 Termination.  This Agreement may be terminated and the
                  -----------
Separation abandoned at any time prior to the Separation Date by and in the sole
discretion of SeraCare without the approval of Life Sciences. In the event of
termination pursuant to this Section 3.17, no party shall have any liability of
any kind to the other party.

     Section 3.18 Survival.  The covenants and other agreements contained herein
                  --------
shall survive the Distribution and continue in effect for a period of one year
following the date of the Distribution and shall terminate on the anniversary of
the Distribution.

     Section 3.19 Third Party Beneficiary.  The parties agree that Instituto
                  -----------------------
Grifols, S.A. shall be an express third party beneficiary to this Agreement.

     Section 3.20 Additional Representations and Warranties.  Life Sciences
                  -----------------------------------------
represents and warrants to SeraCare that (i) all Assets listed in the Life
Sciences Balance Sheet are primarily used in or related to the Life Sciences
Business and (ii) no Assets listed in the Life Sciences Balance Sheet are used
in the collection of blood plasma.

                                  ARTICLE IV
                                  DEFINITIONS

     Section 4.1  Ancillary Agreement.  "Ancillary Agreement" has the meaning
                  -------------------
set forth in Section 2.1 of the Separation Agreement.

     Section 4.2  Assets.  "Assets" means assets, properties and rights
                  ------
(including goodwill), wherever located (including in the possession of vendors
or other third parties or elsewhere), whether real, personal or mixed, tangible,
intangible or contingent, in each case whether or not recorded or reflected or
required to be recorded or reflected on the books and records or financial
statements of any Person, including the following:

          (i)    all accounting and other books, records and files whether in
paper, microfilm, microfiche, computer tape or disc, magnetic tape or any other
form;

          (ii)   all apparatus, computers and other electronic data processing
equipment, fixtures, machinery, equipment, furniture, office equipment,
automobiles, trucks, aircraft, rolling stock, vessels, motor vehicles and other
transportation equipment, special and general tools, test devices, prototypes
and models and other tangible personal property;

          (iii)  all inventories of materials, parts, raw materials, supplies,
work-in-process and finished goods and products;

          (iv)   all interests in real property of whatever nature, including
easements, whether as owner, mortgagee or holder of a Security Interest, lessor,
sublessor, lessee, sublessee or otherwise;

                                     -12-
<PAGE>

          (v)     all interests in any capital stock or other equity interests
of any Subsidiary or any other Person; all bonds, notes, debentures or other
securities issued by any Subsidiary or any other Person; all loans, advances or
other extensions of credit or capital contributions to any Subsidiary or any
other Person; and all other investments in securities of any Person;

          (vi)    all license agreements, leases of personal property, open
purchase orders for raw materials, supplies, parts or services, unfilled orders
for the manufacture and sale of products and other contracts, agreements or
commitments;

          (vii)   all deposits, letters of credit and performance and surety
bonds;

          (viii)  all written technical information, data, specifications,
research and development information, engineering drawings, operating and
maintenance manuals, and materials and analyses prepared by consultants and
other third parties;

          (ix)    all Intellectual Property and licenses from third Persons
granting the right to use any Intellectual Property;

          (x)     all computer applications, programs and other software,
including operating software, network software, firmware, middleware, design
software, design tools, systems documentation and instructions;

          (xi)    all cost information, sales and pricing data, customer
prospect lists, supplier records, customer and supplier lists, customer and
vendor data, correspondence and lists, product literature, artwork, design,
development and manufacturing files, vendor and customer drawings, formulations
and specifications, quality records and reports and other books, records,
studies, surveys, reports, plans and documents;

          (xii)   all prepaid expenses, trade accounts and other accounts and
notes receivables;

          (xiii)  all rights under contracts or agreements, all claims or rights
against any Person arising from the ownership of any Asset, all rights in
connection with any bids or offers and all claims, choses in action or similar
rights, whether accrued or contingent;

          (xiv)   all rights under insurance policies and all rights in the
nature of insurance, indemnification or contribution;

          (xv)    all licenses (including radio and similar licenses), permits,
approvals and authorizations which have been issued by any Governmental
Authority;

          (xvi)   cash or cash equivalents, bank accounts, lock boxes and other
deposit arrangements; and

          (xvii)  interest rate, currency, commodity or other swap, collar, cap
or other hedging or similar agreements or arrangements.

                                     -13-
<PAGE>

     Section 4.3  Consent.  "Consent" means any consent, waiver or approval
                  -------
from, or notification requirement to, any third party or parties.

     Section 4.4  Contract.  "Contract" means any contract, agreement, lease,
                  --------
license, sales order, purchase order, instrument or other commitment that is
binding on any Person or any part of its property under applicable law.

     Section 4.5  Disputes.  "Disputes" has the meaning set forth in Section 9.8
                  --------
of the Separation Agreement.

     Section 4.6  Distribution.  "Distribution" has the meaning set forth in the
                  ------------
Recitals of the Separation Agreement.

     Section 4.7  Distribution Date.  "Distribution Date" has the meaning set
                  -----------------
forth in Section 3.2(a) of the Separation Agreement.

     Section 4.8  Excluded Assets.  "Excluded Assets" has the meaning set forth
                  ---------------
in Section 1.2(b) of this Agreement.

     Section 4.9  Excluded Liabilities.  "Excluded Liabilities" has the meaning
                  --------------------
set forth in Section 1.3(b) of this Agreement .

     Section 4.10 Governmental Approvals.  "Governmental Approvals" means any
                  ----------------------
notices, reports or other filings to be made, or any consents, registrations,
approvals, permits or authorizations to be obtained from, any Governmental
Authority.

     Section 4.11 Governmental Authority.  "Governmental Authority" means any
                  ----------------------
federal, state, local, foreign or international court, government, department,
commission, board, bureau, agency, official or other regulatory, administrative
or governmental authority.

     Section 4.12 Insurance Policies.  "Insurance Policies" means insurance
                  ------------------
policies pursuant to which a Person makes a true risk transfer to an insurer.

     Section 4.13 Insured Life Sciences Liability.  "Insured Life Sciences
                  -------------------------------
Liability" means any Life Sciences Liability to the extent that it is covered
under the terms of SeraCare's Insurance Policies.

     Section 4.14 Intellectual Property.  "Intellectual Property" means all
                  ---------------------
domestic and foreign patents and patent applications, together with any
continuations, continuations-in-part or divisional applications thereof, and all
patents issuing thereon (including reissues, renewals and re-examinations of the
foregoing); design patents, invention disclosures; mask works; copyrights, and
copyright applications and registrations; Web addresses, trademarks, service
marks, trade names, and trade dress, in each case together with any applications
and registrations therefor and all appurtenant goodwill relating thereto; trade
secrets, commercial and technical information, know-how, proprietary or
confidential information, including engineering, production and other designs,
notebooks, processes, drawings, specifications, formulae, and technology;
computer and electronic data processing programs and software (object and source
code), data bases and documentation thereof; inventions (whether patented or
not); utility models; registered designs,

                                     -14-
<PAGE>

certificates of invention and all other intellectual property under the laws of
any country throughout the world.

     Section 4.15 Liabilities.  "Liabilities" has the meaning set forth in
                  -----------
Section 9.24 of the Separation Agreement.

     Section 4.16 Life Sciences Assets. "Life Sciences Assets" has the meaning
                  --------------------
set forth in Section 1.2(a) of this Agreement.

     Section 4.17 Life Sciences Balance Sheet.  "Life Sciences Balance Sheet"
                  ---------------------------
means the unaudited pro forma balance sheet (including the notes thereto)
relating to Life Sciences as of February 28, 2001, attached hereto as Exhibit A.
                                                                      ---------

     Section 4.18 Life Sciences Business.  "Life Sciences Business" has the
                  ----------------------
meaning set forth in Section 9.26 of the Separation Agreement.

     Section 4.19 Life Sciences Contingent Claim.  "Life Sciences Contingent
                  ------------------------------
Claim" means any claim or other right of a member of the SeraCare Group or Life
Sciences Group that primarily relates to the Life Sciences Business, whenever
arising, against any Person other than a member of the SeraCare Group or Life
Sciences Group and the existence or scope of the obligation of such other Person
was not acknowledged, fixed or determined in any material respect, due to a
dispute or other uncertainty or as a result of the failure of such claim or
other right to have been discovered or asserted. A claim or right meeting the
foregoing definition shall be considered a Life Sciences Contingent Claim
regardless of whether there was any Action pending, threatened or contemplated
as of the Separation Date with respect thereto.

     Section 4.20 Life Sciences Contingent Liability.  "Life Sciences Contingent
                  ----------------------------------
Liability" means any Liability of a member of the SeraCare Group or Life
Sciences Group that primarily relates to, results from or arises out of the Life
Sciences Business, whenever arising, to any Person other than a member of the
SeraCare Group or Life Sciences Group, and the existence or scope of the
obligation of a member of the SeraCare Group or Life Sciences Group with respect
to such Liability was not acknowledged, fixed or determined in any material
respect, due to a dispute or other uncertainty or as a result of the failure of
such Liability to have been discovered or asserted.  The parties agree that the
existence of a litigation or other reserve with respect to any Liability shall
not be sufficient for such Liability to be considered acknowledged, fixed or
determined.

     Section 4.21 Life Sciences Contracts.  "Life Sciences Contracts" means the
                  -----------------------
following contracts and agreements to which SeraCare is a party or by which it
or any of its Assets is bound, whether or not in writing, except for any such
contract or agreement that is contemplated to be retained by SeraCare or any
member of the SeraCare Group pursuant to any provision of this Agreement or any
other Ancillary Agreement:

          (i)    the material contracts listed on Schedule 4.30;

          (ii)   any contract or agreement entered into in the name of, or
expressly on behalf of, any division or business unit of Life Sciences;

                                     -15-
<PAGE>

          (iii)  any contract or agreement that relates primarily to the Life
Sciences Business;

          (iv)   any contract or agreement that is otherwise expressly
contemplated pursuant to this Agreement (including, without limitation, the
contracts set forth on Schedule 4.30 hereto), the Separation Agreement or any of
the other Ancillary Agreements to be assigned to Life Sciences; and

          (v)    any guarantee, indemnity, representation, warranty or other
Liability of Life Sciences or the SeraCare Group in respect of any other Life
Sciences Contract, any Life Sciences Liability or the Life Sciences Business
(including guarantees of financing incurred by customers or other third parties
in connection with purchases of products or services from the Life Sciences
Business).

     Section 4.22 Life Sciences Group.  "Life Sciences Group" has the meaning
                  -------------------
set forth in Section 9.27 of the Separation Agreement.

     Section 4.23 Life Sciences Liabilities.  "Life Sciences Liabilities" has
                  -------------------------
the meaning set forth in Section 1.3(a) of this Agreement.

     Section 4.24 Merger.  "Merger" has the meaning set forth in Section 9.31 of
                  ------
the Separation Agreement.

     Section 4.25 Person.  "Person" has the meaning set forth in Section 9.36 of
                  ------
the Separation Agreement.

     Section 4.26 Security Interest.  "Security Interest" means any mortgage,
                  -----------------
security interest, pledge, lien, charge, claim, option, right to acquire, voting
or other restriction, right-of-way, covenant, condition, easement, encroachment,
restriction on transfer, or other encumbrance of any nature whatsoever.

     Section 4.27 Separation.  "Separation" has the meaning set forth in the
                  ----------
Recitals of the Separation Agreement.

     Section 4.28 Separation Agreement.  "Separation Agreement" means the Master
                  --------------------
Separation and Distribution Agreement dated as of the date hereof between the
parties, to which this Agreement is attached as Exhibit C.

     Section 4.29 Separation Date.  "Separation Date" has the meaning set forth
                  ---------------
in Section 1.1 of the Separation Agreement.

     Section 4.30 SeraCare Business.  "SeraCare Business" has the meaning set
                  -----------------
forth in Section 9.42 of the Separation Agreement.

     Section 4.31 SeraCare Group.  "SeraCare Group" has the meaning set forth in
                  --------------
Section 9.43 of the Separation Agreement.

                                     -16-
<PAGE>

     Section 4.32 Subsidiary.  "Subsidiary" means with respect to any specified
                  ----------
Person, any corporation, any limited liability company, any partnership or other
legal entity of which such Person or its Subsidiaries owns, directly or
indirectly, more than 50% of the stock or other equity interest entitled to vote
on the election of the members of the board of directors or similar governing
body.

     Section 4.33 Trademark License Agreement.  "Trademark License Agreement"
                  ---------------------------
means the Trademark License Agreement attached as Exhibit D to the Separation
Agreement.

     Section 4.34 Transferred Litigation.  "Transferred Litigation" has the
                  ----------------------
meaning set forth in Section 2.1(a) of this Agreement.

                                     -17-
<PAGE>

          IN WITNESS WHEREOF, each of the parties has caused this Agreement to
be executed on its behalf by its officers thereunto duly authorized on the day
and year first above written.

SERACARE, INC.                              SERACARE LIFE SCIENCES , INC.

By:     /s/ Barry D. Plost                  By:     /s/ Jerry L. Burdick
        _______________________________             ____________________________
Name:   Barry D. Plost                      Name:   Jerry L. Burdick
Title:  Chief Executive Officer             Title:  Executive Vice President

        [SIGNATURE PAGE TO GENERAL ASSIGNMENT AND ASSUMPTION AGREEMENT]

                                     -18-
<PAGE>

                                Schedule 1.2(a)

                Assets Listed in the Life Sciences Balance Sheet

See Attached.

This schedule 1.2(a) has been omitted and shall be furnished supplementally to
the Commission upon request.
<PAGE>

                                Schedule 1.3(a)

                              Included Liabilities

1.   Any damages, fees and expenses (including, without limitation, actual
     attorneys' fees, arbitrators' fees, costs of experts and court costs)
     payable by SeraCare which have not been paid or incurred as of the date
     hereof in excess of $750,000 arising out of or in connection with the
     following:

     On or about November 11, 2000, Sharon A. Dodson, acting in her capacity as
     trustee of the Crowley Charitable Remainder Unitrust (the "Trust"), filed a
     demand for arbitration in the Orange County, California office of the
     Judicial Arbitration and Mediation Services.  Along with the demand for
     arbitration, Dodson filed a complaint against SeraCare, Inc. (the
     "Complaint") for breach of contract, accounting, and declaratory relief.
     The Complaint alleges that SeraCare breached: (1) a stock purchase
     agreement by which SeraCare purchased The Western States Group, Inc. from
     the Trust and various individuals associated with the Trust; and (2) a
     settlement agreement between SeraCare and the Trust that was entered into
     to resolve a prior dispute regarding SeraCare's obligations under the stock
     purchase agreement

2.   Subject to item 1 above, any and all indemnification obligations of
     SeraCare pursuant to, arising out of or resulting from the Stock  Purchase
     Agreement dated as of February 13, 1998, by and among SeraCare, Inc., The
     Western States Group, Inc., Michael F. Crowley, Mary A. Crowley, Michael F.
     Crowley and Mary A. Crowley as trustees under the Crowley Charitable
     Remainder Unitrust dated December 31, 1997, and Michael F. Crowley, II.

3.   All Liabilities arising out of or resulting from the Collaboration
     Agreement dated January 1, 2001 between SeraCare and Quest Diagnostics
     Incorporated, a Delaware corporation, existing or arising prior to, or
     after the Separation Date, other than any liabilities relating to payments
     due from Instituto Grifols, S.A. to Quest Diagnostics Incorporated in
     connection with the Warrant issued to Quest on November 20, 2000 to
     purchase 1,748,605 shares of common stock of SeraCare (as may be modified
     in accordance with Section 3.5 of the Company Disclosure Letter to the
     Merger Agreement).

4.   All Liabilities relating to counterclaims arising primarily from the
     operation of the Life Sciences Business and resulting from and arising out
     of the litigation identified in Item 1 to Schedule 2.1(a).

5.   All Liabilities arising from the Cease and Desist letter dated March 9,
     2001, from Intergen Company to SeraCare relating to the Company's alleged
     contact of certain of Intergen's ex-employees for the purpose of acquiring
     confidential information about Intergen.

                                      -2-
<PAGE>

                                Schedule 1.3(b)

                              Excluded Liabilities

1.   Any damages, fees and expenses (including, without limitation, attorneys'
     fees, arbitrators' fees, costs of experts and court costs) payable by
     SeraCare which have not been paid or incurred as of the date hereof up to
     $750,000 arising out of or in connection with the following:

     On or about November 11, 2000, Sharon A. Dodson, acting in her capacity as
     trustee of the Crowley Charitable Remainder Unitrust (the "Trust"), filed a
     demand for arbitration in the Orange County, California office of the
     Judicial Arbitration and Mediation Services.  Along with the demand for
     arbitration, Dodson filed a complaint against SeraCare, Inc. (the
     "Complaint") for breach of contract, accounting, and declaratory relief.
     The Complaint alleges that SeraCare breached: (1) a stock purchase
     agreement by which SeraCare purchased The Western States Group, Inc. from
     the Trust and various individuals associated with the Trust; and (2) a
     settlement agreement between SeraCare and the Trust that was entered into
     to resolve a prior dispute regarding SeraCare's obligations under the stock
     purchase agreement.

2.   Attorneys' fees, financial advisors' and investment banking fees,
     accountant's fees and other expenses incurred by SeraCare or Life Sciences
     in connection with the Merger and the Separation and Distribution.

3.   Liabilities relating to the business of the collection of blood plasma.

4.   Liabilities relating to payments due from Instituto Grifols, S.A. to Quest
     Diagnostics Incorporated in connection with the Warrant issued to Quest on
     November 20, 2000 to purchase 1,748,605 shares of common stock of SeraCare
     (as may be modified in accordance with Section 3.5 of the Company
     Disclosure Letter to the Merger Agreement.)

                                      -3-
<PAGE>

                                Schedule 2.1(a)

                             Transferred Litigation

1.   On March 29, 2001, SeraCare instituted an action in Superior Court for the
     County of San Diego, Vista Branch, entitled Western States Group, Inc., dba
     Western States Plasma Company, SeraCare, Inc. v. The Trilogy Connection,
     Inc., David Betit, R. Craig Harlow, Intergen Company L.P., Canon
     Communications LLC ("Cannon") and Does 1-100, inclusive, Case No. GIN
     011713 (the "Action").  The Action alleges that authors David Betit and R.
     Craig Harlow fraudulently obtained plasma samples from SeraCare and
     conducted rigged "scientific" tests on those samples to favor the authors'
     marketing client, Intergen Company.  The lawsuit alleges defamation, unfair
     business practices and fraud, and seeks injunctive relief and an
     unspecified amount of damages.  On June 5, 2001, SeraCare settled its
     claims against Canon by entering into a written settlement agreement.
     Under the terms of the settlement, SeraCare has agreed to dismiss the
     Action with prejudice as to Canon in exchange for receiving three free
     advertisements in Canon's magazine, IVD Technology.

                                      -4-
<PAGE>

                                Schedule 2.1(b)

1.   The management and all liabilities, costs and expenses (including without
     limitation all attorneys' fees and expenses) with respect to the
     Transferred Litigation identified in Item 1 to Schedule 2.1(a) hereto shall
     be the sole responsibility of Life Sciences and the SeraCare Group shall
     have no liability or responsibility with respect thereto.

2.   Any damages, fees and expenses (including, without limitation, attorneys'
     fees, arbitrators' fees, costs of experts and court costs) payable by
     SeraCare which have not been paid or incurred as of the date hereof up to
     $750,000 arising out of or in connection with the matter identified in Item
     1 to Schedule 1.3(b) hereto shall be the sole responsibility of SeraCare
     and Life Sciences shall have no liability or responsibility with respect
     thereto.

3.   Any damages, fees and expenses (including, without limitation, attorneys'
     fees, arbitrators' fees, costs of experts and court costs) payable by
     SeraCare which have not been paid or incurred as of the date hereof in
     excess of $750,000 arising out of or in connection with matter identified
     in Item 1 to Schedule 1.3(b) hereto shall be the sole responsibility of
     Life Sciences and the SeraCare Group shall have no liability or
     responsibility with respect thereto.

4.   The management and all liabilities, costs and expenses (including without
     limitation all attorneys' fees and expenses) with respect to the Cease and
     Desist letter dated March 9, 2001, from Intergen Company to SeraCare
     identified in Item 5 to Schedule 1.3(a) hereto shall be the sole
     responsibility of Life Sciences and the SeraCare Group shall have no
     liability or responsibility with respect thereto.

5.   The indemnification rights relating to the Life Sciences Business in favor
     of SeraCare in the Stock Purchase Agreement dated February 13, 1998 among
     SeraCare, Inc., The Western States Group, Inc., Michael Crowley, and
     individual, Mary Crowley, an individual, Michael F. Crowley, Mary A.
     Crowley as trustees under the Crowley Charitable Remainder Unitrust dated
     December 31, 1997 and Michael F. Crowley II shall belong solely to Life
     Sciences.

                                      -5-
<PAGE>

                                 Schedule 4.30

                               Material Contracts

1.   Agreement between AMPC, Inc., and SeraCare, Inc. dated October 21, 1999.

2.   Standard Industrial/Commercial Multi-Tennant Lease - Gross between Del Oro
     Gateway Partners, L.P. and  The Western States Group Inc. dated as of April
     16, 1998, and addendums attached thereto dated on or about October 12, 1998
     and January 7, 1999, and assignment agreement dated ___, 2001 among Del Oro
     Gateway Partners, L.P. and Arthur Kazarian as trustee for the General Wood
     Investment Trust (Del Oro Gateway Commerce Centre, 1935 Avenida del Oro,
     suite F, Oceanside, California).

3.   Collaboration Agreement dated January 1, 2001 between the Company and Quest
     Diagnostics Incorporated, a Delaware corporation.

4.   Albumin Supply Agreement dated June 22, 1999 between Instituto Grifols,
     S.A., and SeraCare, Inc., as amended

5.   Employment Agreement between SeraCare, Inc. and Michael F. Crowley II,
     dated November 1, 2000.

                                      -6-
<PAGE>

                                   EXHIBIT A

                          LIFE SCIENCES BALANCE SHEET

(see attached)

This Exhibit A has been omitted and shall be furnished supplementally to the
Commission upon request.

                                      -7-
<PAGE>

                                   EXHIBIT B

NETWORK SOLUTIONS TRANSFER AGREEMENT

This Exhibit B has been omitted and shall be furnished supplementally to the
commission upon request.

                                      -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}]]